How many Empagliflozin clinical trials are there?

428 Empagliflozin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 84 are actively recruiting participants. 215 are marked completed.

Are Empagliflozin clinical trials recruiting in 2026?

Yes — 84 Empagliflozin trials are actively recruiting in 2026, with 412 U.S. sites across 44 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Empagliflozin being studied for?

Empagliflozin is being studied for Diabetes Mellitus, Type 2, Heart Failure, Type 2 Diabetes, Healthy, Type 2 Diabetes Mellitus and 319 more. The trials are grouped by indication on this page.

What phase is Empagliflozin in?

Empagliflozin clinical trials span 116 Phase 4, 78 Phase 3, 68 Phase 2, 64 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Empagliflozin clinical trials?

The lead sponsor across the most Empagliflozin trials is Boehringer Ingelheim, with 223 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Empagliflozin Clinical Trials (2026): 428 Studies for Diabetes Mellitus, Type 2 & Heart Failure

Creator: Hipa.ai Research
Published: 2026-05-08T19:29:20.742Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 26, 2026.

428 Empagliflozin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 188 indications (including Diabetes Mellitus, Type 2 & Heart Failure) and 3,862,380 total planned enrollment. 78 Phase 3 Empagliflozin trials and 68 Phase 2, 116 Phase 4 are listed. 101 Empagliflozin clinical trials are actively recruiting at 412 U.S. sites across 44 states. Most recent activity: NCT04381936 (Sep 2038).

Where to Participate: All Empagliflozin Trial Sites in the U.S. (412 sites across 44 states)

Every actively recruiting Empagliflozintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Pinnacle Research Group, LLC	Anniston36207	NCT07064473	Map
AL	CON-10004 Fairhope, AL Investigational Site	Fairhope36532	NCT06024746	Map
AL	Eastern Shore Research Group	Fairhope36532	NCT07064473	Map
AL	Lakeview Clinical Research	Guntersville35976	NCT07064473	Map
AL	Apogee Clinical Research	Huntsville35805-4104	NCT06531824	Map
AL	Mobile Heart Specialists, PC	Mobile36608	NCT06424288	Map
AZ	Arizona Clinical Trials - Chandler	Chandler85225	NCT07064473	Map
AZ	Elite Clinical Studies	Phoenix85018	NCT07064473	Map
AZ	Clinical Research Institute of Arizona, LLC	Sun City West85375	NCT07064473	Map
AZ	Southwest Kidney Institute	Surprise85374-4840	NCT06531824	Map
AZ	Fiel Family & Sports Medicine	Tempe85283	NCT07064473	Map
AZ	Arizona Clinical Trials	Tucson85711	NCT07064473	Map
AZ	Yuma Clinical Trials	Yuma85364	NCT07064473	Map
CA	Cure Clinical Research	Beverly Hills90211	NCT06935370	Map
CA	National Heart Institute	Beverly Hills90211	NCT07064473	Map
CA	Hope Clinical Research	Canoga Park91303	NCT07064473	Map
CA	Velocity Clinical Research-Chula Vista	Chula Vista91911	NCT06424288	Map
CA	John Muir Physician Network Clinical Research Center	Concord94520	NCT07064473	Map
CA	Valley Clinical Trials, Inc.	Covina91723	NCT06935370	Map
CA	CON-10075 El Centro, CA Investigational Site	El Centro92243	NCT06024746	Map
CA	Velocity Clinical Research-Huntington Park	Huntington Park90255	NCT07064473	Map
CA	Velocity Clinical Research, San Diego	La Mesa91942	NCT07064473	Map
CA	First Valley Medical Group	Lancaster93534	NCT07064473	Map
CA	ARK Clinical Research	Long Beach90815	NCT07064473	Map
CA	Merced Vein and Vascular Center	Merced95340	NCT06935370	Map
CA	Diabetes Associates Medical Group	Orange92868	NCT07064473	Map
CA	CON-10024 Sacramento, CA Investigational Site	Sacramento95816	NCT06024746	Map
CA	Velocity Clinical Research - San Bernardino	San Bernardino92408	NCT07064473	Map
CA	Acclaim Clinical Research	San Diego92120	NCT07064473	Map
CA	North America Research Institute	San Dimas91773	NCT06424288	Map
CA	Amicis Research Center - Valencia	Santa Clarita91355	NCT06424288	Map
CA	NorthBay Clinical Research, LLC	Santa Rosa95405	NCT07064473	Map
CA	Orange County Research Center	Tustin92780	NCT06424288	Map
CA	Blue Coast Research Center, LLC	Vista92081	NCT07064473	Map
CO	Rocky Mountain Regional VA Medical Center	Aurora80045	NCT07064473	Map
CT	Cardiology Physicians of Fairfield County - Bridgeport	Bridgeport06606	NCT07064473	Map
CT	CMR of Greater New Haven, LLC	Hamden06517	NCT07064473	Map
CT	Yale New Haven Hospital	New Haven06520	NCT05553938	Map
CT	Yale University	New Haven06520	NCT05553938	Map
CT	Yale University	New Haven06510	NCT05671991	Map
CT	Yale University	New Haven06510	NCT05726032	Map
CT	Cardiology Associates of Fairfield County	Stamford06905	NCT07064473	Map
DC	Washington DC Veterans Affairs Medical Center (688)	Washington D.C.20422	NCT06110130	Map
FL	Excel Medical Clinical Trials	Boca Raton33434	NCT06424288	Map
FL	Excel Medical Clinical Trials	Boca Raton33434	NCT07064473	Map
FL	Bay Area Cardiology	Brandon33511	NCT06424288	Map
FL	Bay Area Cardiology	Brandon33511	NCT06935370	Map
FL	Clearwater Cardiovascular and Interventional Consultants	Clearwater33756	NCT06424288	Map
FL	Clinical Research of West Florida, Inc.	Clearwater33765	NCT07064473	Map
FL	Beautiful Minds Clinical Research Center	Cutler Bay33157	NCT07064473	Map
FL	Cardiology Associates Research Co.	Daytona Beach32117	NCT06424288	Map
FL	Cardiology Associates Research Co.	Daytona Beach32117	NCT06935370	Map
FL	Hillcrest Medical Research	DeLand32720	NCT07064473	Map
FL	University Clinical Research Deland, LLC	DeLand32720	NCT07064473	Map
FL	Suncoast Research Associates, LLC	Doral33172	NCT06935370	Map
FL	Universal Axon Clinical Research	Doral33166	NCT07064473	Map
FL	Northeast Research Institute	Fleming Island32003	NCT07064473	Map
FL	Covenant Metabolic Specialists, LLC - Fort Myers	Fort Myers33912	NCT07064473	Map
FL	Malcom Randall VA Medical Center	Gainesville32608	NCT06424288	Map
FL	Malcom Randall VA Medical Center	Gainesville32608	NCT06935370	Map
FL	Velocity Clinical Research-Hallandale Beach-67888	Hallandale33009	NCT06424288	Map
FL	Velocity Clinical Research-Hallandale Beach-67888	Hallandale33009	NCT06935370	Map
FL	Velocity Clinical Research-Hallandale Beach-67888	Hallandale33009	NCT07064473	Map
FL	Indago Research and Health Center	Hialeah33012	NCT07064473	Map
FL	East Coast Institute For Research, LLC	Jacksonville32216	NCT06935370	Map
FL	East Coast Institute for Research, LLC - Jacksonville	Jacksonville32216	NCT06424288	Map
FL	East Coast Institute for Research, LLC - Southside	Jacksonville32216	NCT07064473	Map
FL	First Coast Cardiovascular Institute	Jacksonville32256	NCT06424288	Map
FL	Jacksonville Center for Clinical Research	Jacksonville32216	NCT06935370	Map
FL	Jacksonville Center for Clinical Research	Jacksonville32216	NCT07064473	Map
FL	Northeast Research Institute	Jacksonville32204	NCT07064473	Map
FL	University of Florida	Jacksonville32209	NCT06935370	Map
FL	University of Florida Health Jacksonville	Jacksonville32209	NCT06424288	Map
FL	Westside Center for Clinical Research	Jacksonville32205	NCT07064473	Map
FL	Florida Kidney Physicians LLC	Jacksonville Beach32250-4303	NCT06531824	Map
FL	East Coast Institute for Research - Lake City	Lake City32055	NCT07064473	Map
FL	Clinical Research of Central Florida - Lakeland	Lakeland33805	NCT07064473	Map
FL	Clearwater Cardiovascular Consultants-Largo-69917	Largo33777	NCT06424288	Map
FL	Alma Clinical Research, Inc.	Miami33184	NCT07064473	Map
FL	Finlay Medical Research Corp	Miami33126	NCT07064473	Map
FL	IMIC Inc.	Miami33176	NCT07064473	Map
FL	Infinite Clinical Research Inc	Miami33133	NCT06935370	Map
FL	Oceane7 Clinical Research	Miami33144	NCT07064473	Map
FL	Optimus U Corporation-Miami-69452	Miami33135	NCT07064473	Map
FL	Research Institute of South Florida, Inc.	Miami33173	NCT07064473	Map
FL	Total Research Group, LLC	Miami33126	NCT06531824	Map
FL	Inpatient Research Clinic, LLC	Miami Lakes33014	NCT06935370	Map
FL	Sacred Heart Medical Specialty Group	Miramar Beach32550	NCT06424288	Map
FL	Advanced Research for Health Improvement, LLC	Naples34102	NCT07064473	Map
FL	Southwest Florida Research, LLC	Naples34102	NCT06424288	Map
FL	Suncoast Clinical Research	New Port Richey34652	NCT07064473	Map
FL	Ocala Cardiovascular Research	Ocala34471	NCT06424288	Map
FL	Ocala Research Institute, Inc	Ocala34471	NCT06424288	Map
FL	Florida Institute for Clinical Research	Orlando32825	NCT07064473	Map
FL	Ormond Beach Clinical Research	Ormond Beach32174	NCT07064473	Map
FL	Cardiology Partners Clinical Research Institute	Palm Beach Gardens33410	NCT07064473	Map
FL	Innovation Medical Research Center	Palmetto Bay33157	NCT06935370	Map
FL	Center for Diabetes, Obesity and Metabolism	Pembroke Pines33024	NCT07064473	Map
FL	Charlotte Cardiovascular Institute, PA	Port Charlotte33952	NCT06424288	Map
FL	Peace River Cardiovascular Center	Port Charlotte33952	NCT06935370	Map
FL	Peace River Cardiovascular Center	Port Charlotte33952	NCT07064473	Map
FL	East Coast Institute for Research, LLC-Saint Augustine-63032	Saint Augustine32086	NCT06424288	Map
FL	East Coast Institute for Research, LLC-Saint Augustine-63032	Saint Augustine32086	NCT07064473	Map
FL	St. Johns Center for Clinical Research	Saint Augustine32086	NCT06935370	Map
FL	IMA Clinical Research St. Petersburg	St. Petersburg33704	NCT07064473	Map
FL	Covenant Metabolic Specialists, LLC - Sarasota	University Park34201	NCT07064473	Map
FL	Cardiology Partners Clinical Research Institute	Wellington33449	NCT06424288	Map
FL	Cardiology Partners Clinical Research Institute	Wellington33449	NCT06935370	Map
FL	Cardiology Partners Clinical Research Institute	Wellington33449	NCT07064473	Map
FL	Cozy Research LLC	Wesley Chapel33544	NCT06424288	Map
FL	Cozy Research LLC	Wesley Chapel33544	NCT06935370	Map
FL	Clinical Site Partners, LLC	Winter Park32789	NCT06424288	Map
FL	Clinical Site Partners, LLC	Winter Park32789	NCT06935370	Map
GA	Atlanta Clinical Research Centers	Atlanta30342	NCT06424288	Map
GA	Atlanta Clinical Research Centers	Atlanta30342	NCT06935370	Map
GA	CON-10022 Atlanta, GA Investigational Site	Atlanta30303	NCT06024746	Map
GA	Centricity Research, Endocrine Consultants	Columbus31904	NCT07064473	Map
GA	Columbus Regional Research Institute	Columbus31904	NCT06424288	Map
GA	Joseph Maxwell Cleland Atlanta VA Medical Center	Decatur30033-4004	NCT06531824	Map
GA	NSC Research Inc	Johns Creek30024	NCT06424288	Map
GA	NSC Research Inc	Johns Creek30024	NCT06935370	Map
GA	NSC Research Inc	Johns Creek30024	NCT07064473	Map
GA	East Coast Institute For Research LLC	Macon31210-1359	NCT06531824	Map
GA	The Jones Center for Diabetes and Endocrine Wellness	Macon31210	NCT07064473	Map
GA	Urban Family Practice Associates, PC	Marietta30067	NCT07064473	Map
GA	Javara-Savannah-67450	Savannah31406	NCT07064473	Map
GA	Javara Research - Thomasville	Thomasville31792	NCT07064473	Map
GA	Atlanta Heart Specialists, LLC	Tucker30084	NCT07064473	Map
HI	Pacific Diabetes & Endocrine Center	Honolulu96817	NCT07064473	Map
ID	Kootenai Medical Center	Coeur d'Alene83814	NCT06424288	Map
ID	Kootenai Research Services	Coeur d'Alene83814	NCT06531824	Map
ID	Rocky Mountain Clinical Research - Idaho Falls	Idaho Falls83404	NCT07064473	Map
IL	Northwest Heart Clinical Research, LLC	Arlington Heights60005	NCT06424288	Map
IL	Ann & Robert H Lurie Children's Hospital of Chicago	Chicago60611	NCT06355310	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT06430684	Map
IL	Illinois Masonic Hospital	Chicago60657	NCT06424288	Map
IL	Northwestern University	Chicago60611	NCT06531824	Map
IL	University of Chicago	Chicago60637	NCT07055282	Map
IL	University of Illinois Chicago, Sickle Cell Center	Chicago60302	NCT07175051	Map
IL	Chicago Medical Research	Hazel Crest60429	NCT06424288	Map
IL	Chicago Medical Research	Hazel Crest60429	NCT06935370	Map
IL	Edward Hines Jr. VA Hospital, Hines, IL	Hines60141-3030	NCT06013865	Map
IL	Clinical Investigation Specialists, Inc.	Libertyville60048	NCT06935370	Map
IL	Clinical Investigation Specialists, Inc.-Libertyville-69941	Libertyville60048	NCT06424288	Map
IL	AMR Park Ridge	Park Ridge60068	NCT06424288	Map
IL	AMR Park Ridge	Park Ridge60068	NCT06935370	Map
IL	Springfield Clinic	Springfield62703	NCT06935370	Map
IN	American Health Network - Avon	Avon46123	NCT07064473	Map
IN	Midwest Cardiovascular Research and Education Foundation	Elkhart46514	NCT06424288	Map
IN	Midwest Cardiovascular Research and Education Foundation	Elkhart46514	NCT07064473	Map
IN	American Health Network - Franklin	Franklin46131	NCT07064473	Map
IN	American Health Network - Greenfield	Greenfield46140	NCT07064473	Map
IN	Indiana University	Indianapolis46202	NCT07107945	Map
IN	St. Francis Medical Group-Indiana Heart Physicians, Inc	Indianapolis46237	NCT06424288	Map
IN	St. Francis Medical Group-Indiana Heart Physicians, Inc	Indianapolis46237	NCT06935370	Map
IN	Indiana Medical Research Institute	Merrillville46410	NCT06424288	Map
IN	American Health Network - Muncie	Muncie47304	NCT07064473	Map
IN	Cardiovascular Research of Northwest Indiana, LLC	Munster46321	NCT06424288	Map
IN	Cardiovascular Research of Northwest Indiana, LLC	Munster46321	NCT06935370	Map
IN	Reid Hospital	Richmond47374	NCT06424288	Map
IN	Reid Hospital	Richmond47374	NCT06935370	Map
IN	Reid Physician Associates	Richmond47374	NCT07064473	Map
IA	Iowa City VA Health Care System, Iowa City, IA	Iowa City52246-2292	NCT06013865	Map
IA	The Iowa Clinic, PC	West Des Moines50266	NCT06424288	Map
IA	The Iowa Clinic, PC	West Des Moines50266	NCT06935370	Map
KS	AMR El Dorado	El Dorado67042	NCT07064473	Map
KS	University of Kansas Medical Center	Kansas City66160	NCT06531824	Map
KS	Cotton O'Neil Diabetes & Endocrinology Center	Topeka66606	NCT07064473	Map
KS	Kansas Nephrology Research Institute, LLC	Wichita67214	NCT06531824	Map
KS	Kansas Nephrology Research Institute, LLC	Wichita67214	NCT06935370	Map
KS	Robert J Dole Veterans Affairs Medical Center	Wichita67218	NCT06935370	Map
KS	Tekton Research - Wichita	Wichita67218	NCT07064473	Map
KS	West Houston Area Clinical Trial Consultants, LLC	Wichita67226	NCT06424288	Map
KS	West Houston Area Clinical Trial Consultants, LLC	Wichita67226	NCT06935370	Map
KY	Qualmedica Research - Bowling Green	Bowling Green42101	NCT07064473	Map
KY	The Research Group of Lexington	Lexington40503	NCT07064473	Map
KY	Research Integrity, LLC	Owensboro42303	NCT07064473	Map
LA	CON-10030 Baton Rouge, LA Investigational Site	Baton Rouge70808	NCT06024746	Map
LA	Grace Research, LLC-Bossier City-51040	Bossier City71111	NCT06424288	Map
LA	Louisiana Heart Center - Covington	Covington70433	NCT07064473	Map
LA	Heart Clinic of Hammond	Hammond70403	NCT06424288	Map
LA	Heart Clinic of Hammond	Hammond70403	NCT06935370	Map
LA	IMA Clinical Research Monroe	Monroe71201	NCT07064473	Map
LA	Grace Research, LLC-Shreveport-64616	Shreveport71105	NCT06424288	Map
LA	Louisiana Heart Center - Slidell	Slidell70458	NCT06424288	Map
LA	Louisiana Heart Center - Slidell	Slidell70458	NCT07064473	Map
LA	Monroe Research, LLC	West Monroe71291	NCT07064473	Map
LA	Southern Clinical Research - Zachary	Zachary70791	NCT07064473	Map
MD	Ascension Saint Agnes Heart Care	Baltimore21229	NCT06424288	Map
MD	Ascension Saint Agnes Heart Care	Baltimore21229	NCT06935370	Map
MD	Ascension Saint Agnes Heart Care	Baltimore21229	NCT07064473	Map
MD	Medstar Health Research Institute	Baltimore21239	NCT06531824	Map
MD	Metropolitan Cardiovascular Consultants	Beltsville20705	NCT06935370	Map
MD	Capitol Cardiology Associates	Lanham20706	NCT06935370	Map
MD	MD Medical Research	Oxon Hill20745	NCT07064473	Map
MD	TidalHealth, Inc.	Salisbury21804	NCT07064473	Map
MA	Brigham and Women's Hospital	Boston021215	NCT05786443	Map
MA	Massachusetts General Hospital	Boston02144	NCT06674109	Map
MA	ActivMed Practices & Research	Methuen01844	NCT07064473	Map
MI	Cardiology and Vascular Associates - CAVA	Bloomfield Hills48304	NCT06935370	Map
MI	AMR Dearborn	Dearborn48126	NCT06424288	Map
MI	Revival Research Institute, LLC - Dearborn	Dearborn48126	NCT07064473	Map
MI	Michigan Healthcare Professionals Pulse Cardiology	Farmington Hills48334	NCT06935370	Map
MI	Aa Mrc Llc	Flint48504	NCT07064473	Map
MI	Elite Research Center, LLC	Flint48532	NCT07064473	Map
MI	Sparrow Clinical Research Institute	Lansing48910-0826	NCT06424288	Map
MI	Lake Michigan Nephrology	Saint Joseph49085-8511	NCT06531824	Map
MI	St. Clair Nephrology Research, LLC	Shelby48315	NCT06531824	Map
MI	Oakland Medical Center	Troy48085	NCT07064473	Map
MI	Trinity Health Michigan D/B/A Michigan Heart	Ypsilanti48197	NCT06424288	Map
MN	M Health Fairview Masonic Children's Hospital	Minneapolis55454	NCT07107945	Map
MN	Minneapolis VA Health Care System	Minneapolis55417	NCT06424288	Map
MN	Minneapolis VA Health Care System	Minneapolis55417	NCT06531824	Map
MN	University of Minnesota	Minneapolis55414	NCT06507657	Map
MN	Mayo Clinic	Rochester55905	NCT06729996	Map
MN	Metro-Minnesota Community Oncology Research Consortium	Saint Paul55101-2502	NCT03424005	Map
MS	Prime Health and Wellness	Fayette39069	NCT07064473	Map
MS	Jackson Heart Clinic, P.A.	Jackson39216	NCT06424288	Map
MO	Harry S. Truman Memorial, Columbia, MO	Columbia65201-5275	NCT06745063	Map
MO	University of Missouri	Columbia65211	NCT06506422	Map
MO	Jefferson City Medical Group	Jefferson City65109	NCT07064473	Map
MO	Clinical Research Consultants, LLC	Kansas City64111	NCT07064473	Map
MO	CON-10002 Kansas City, MO Investigative Site	Kansas City64111	NCT06024746	Map
MO	St. Louis Heart and Vascular, P.C.	St Louis63136	NCT06424288	Map
MO	St. Louis Heart and Vascular, P.C.	St Louis63136	NCT06935370	Map
MO	Sundance Clinical Research, LLC	St Louis63141	NCT07064473	Map
MT	Billings Clinic - Billings	Billings59101	NCT07064473	Map
NE	Methodist Physicians Clinic	Fremont68025	NCT07064473	Map
NE	Velocity Clinical Research-Lincoln-69943	Lincoln68506	NCT06424288	Map
NE	Great Plains Nephrology	North Platte69101-0614	NCT06531824	Map
NE	Be Well Clinical Studies	Omaha68144	NCT06935370	Map
NE	Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE	Omaha68105-1850	NCT06013865	Map
NE	Quality Clinical Research - Omaha	Omaha68114	NCT07064473	Map
NV	AB Clinical Trials	Las Vegas89119	NCT07064473	Map
NV	Las Vegas Clinical Trials	Las Vegas89030	NCT07064473	Map
NV	Palm Research Center	Las Vegas89128	NCT07064473	Map
NV	Palm Research Center	Las Vegas89148	NCT07064473	Map
NV	Vector Clinical Trials	Las Vegas89128	NCT07064473	Map
NV	Sierra Nevada Specialty Care	Reno89511	NCT06531824	Map
NH	Seacoast Kidney and Hypertension Specialists	Portsmouth03801	NCT06531824	Map
NJ	Advanced Heart Care, LLC	Bridgewater08807	NCT06424288	Map
NJ	Advanced Heart Care, LLC	Bridgewater08807	NCT06935370	Map
NJ	Advanced Heart Care, LLC	Bridgewater08807	NCT07064473	Map
NJ	NJ Heart LLC	Linden07036	NCT07064473	Map
NJ	Garden State Heart Care, PC	Manalapan07726	NCT06424288	Map
NJ	Cardio Metabolic Institute	Somerset08873	NCT06424288	Map
NJ	Cardio Metabolic Institute	Somerset08873	NCT07064473	Map
NM	New Mexico Clinical Research and Osteoporosis Center, Inc.	Albuquerque87106	NCT07064473	Map
NM	UNM Health Science Center	Albuquerque87106	NCT06531824	Map
NY	Velocity Clinical Research - Binghamton	Binghamton13905	NCT07064473	Map
NY	RCR - Buffalo	Buffalo14217	NCT07064473	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06935370	Map
NY	Mount Sinai Hospital-New York-52529	New York10029	NCT06424288	Map
NY	Mount Sinai Hospital-New York-52529	New York10019	NCT06935370	Map
NY	NYC Research Inc.	New York10016	NCT07064473	Map
NY	NYU Langone Health	New York10016	NCT05757791	Map
NY	NYU Langone Health	New York10016	NCT05786443	Map
NY	Rochester Clinical Research, Inc	Rochester14609	NCT07064473	Map
NY	Cardiac Care and Vascular Medicine, PLLC	The Bronx10469	NCT06424288	Map
NY	Southgate Medical Group/ Southgate Medical Park	West Seneca14224	NCT07064473	Map
NY	Great Lakes Medical Research	Westfield14787	NCT07064473	Map
NC	Cary Cardiology	Cary27518	NCT07064473	Map
NC	The University of North Carolina at Chapel Hill	Chapel Hill27514	NCT07064473	Map
NC	Metrolina Nephrology Associates, PA	Charlotte28208-0014	NCT06531824	Map
NC	Metrolina Nephrology Associates, PA	Charlotte28277	NCT06531824	Map
NC	Carolina Kidney Associates	Greensboro27405-3654	NCT06531824	Map
NC	Medication Management, LLC	Greensboro27405	NCT06424288	Map
NC	Physicians East, PA	Greenville27834	NCT07064473	Map
NC	IMA Clinical Research Lenoir	Lenoir28645	NCT06935370	Map
NC	IMA Clinical Research Lenoir	Lenoir28645	NCT07064473	Map
NC	Accellacare-Mooresville-69123	Mooresville28117	NCT07064473	Map
NC	Lucas Research, Inc.	Morehead City28557	NCT07064473	Map
NC	Piedmont Healthcare, Inc.	Statesville28625	NCT06935370	Map
NC	Wilmington Health	Wilmington28401	NCT06935370	Map
NC	Brookview Hills Research Associates LLC	Winston-Salem27103	NCT06531824	Map
NC	Wake Forest University Health Sciences-Winston-Salem-61707	Winston-Salem27157	NCT07064473	Map
ND	Lillestol Research, LLC	Fargo58104	NCT07064473	Map
OH	Velocity Clinical Research-Cincinnati-69044	Cincinnati45242	NCT07064473	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT06531824	Map
OH	Centricity Research-Columbus-68879	Columbus43213	NCT07064473	Map
OH	Remington-Davis Clinical Research, Inc	Columbus43215	NCT07064473	Map
OH	K and R Research LLC	Marion43302	NCT06424288	Map
OH	K and R Research LLC	Marion43302	NCT06935370	Map
OH	Clinical Research Institute of Ohio, LLC	Westlake44145	NCT07064473	Map
OK	Tekton Research-Edmond-68875	Edmond73013	NCT07064473	Map
OK	South Oklahoma Heart Research Group	Oklahoma City73135	NCT07064473	Map
OK	Tekton Research-Yukon-68998	Yukon73099	NCT07064473	Map
PA	Heritage Valley Medical Group	Beaver15009	NCT07064473	Map
PA	Capital Area Research, LLC	Camp Hill17011	NCT07064473	Map
PA	Northeast Endocrine Metabolic Associates	Philadelphia19114-1028	NCT06531824	Map
PA	Thomas Jefferson University	Philadelphia19107	NCT07064473	Map
PA	Tristar Clinical Investigations PC	Philadelphia19114	NCT07064473	Map
PA	University of Pennsylvania Health System	Philadelphia19104	NCT05138575	Map
PA	Children's Hospital of Pittsburgh	Pittsburgh15224	NCT06260059	Map
PA	Magee Women's Hospital	Pittsburgh15213	NCT06260059	Map
PA	Preferred Primary Care Physicians-Pittsburgh-63932	Pittsburgh15236	NCT07064473	Map
PA	Preferred Primary Care Physicians, Inc	Pittsburgh15243	NCT07064473	Map
PA	Presbyterian Hospital	Pittsburgh15213	NCT06260059	Map
PA	VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA	Pittsburgh15240	NCT06013865	Map
PA	Frontier Clinical Research LLC - Scottdale	Scottdale15683	NCT07064473	Map
PA	Frontier Clinical Research	Smithfield15478	NCT07064473	Map
PA	Preferred Primary Care Physicians-Uniontown-69137	Uniontown15401	NCT07064473	Map
PA	Clinical Renal Associates	Upland19013	NCT06531824	Map
PA	Suburban Research Associates	West Chester19380	NCT07064473	Map
PA	Cardiology Consultants of Philadelphia	Yardley19067	NCT06935370	Map
PA	Cardiology Consultants of Philadelphia	Yardley19067	NCT07064473	Map
RI	Nephrology Associates, Inc	East Providence02914-2641	NCT06531824	Map
SC	Piedmont Research Partners, LLC	Fort Mill29707	NCT07064473	Map
SC	Velocity Clinical Research-Gaffney-69046	Gaffney29340	NCT07064473	Map
SC	Bon Secours Medical Group Greenville Specialty Care, LLC	Greenville29607	NCT06424288	Map
SC	Tribe Clinical Research LLC	Greenville29607	NCT07064473	Map
SC	Velocity Clinical Research-Union-68888	Union29379	NCT07064473	Map
SD	Dunes Clinical Research	Dakota Dunes57049	NCT07064473	Map
SD	Monument Health	Rapid City57701	NCT06424288	Map
TN	Tennessee Oncology - Chattanooga Oncology & Hematology Associates	Chattanooga37404	NCT03424005	Map
TN	The West Clinic	Germantown38138	NCT03424005	Map
TN	Helios CR Inc	Jackson38305	NCT06424288	Map
TN	East Coast Institute For Research LLC	Jefferson City37760	NCT06424288	Map
TN	Alliance for Multispecialty Research, LLC-Knoxville-69693	Knoxville37909	NCT07064473	Map
TN	University of Tennessee	Memphis38104	NCT06531824	Map
TN	Tennessee Oncology PLLC	Nashville37203	NCT03424005	Map
TN	Tennessee Valley Healthcare System Nashville Campus, Nashville, TN	Nashville37212-2637	NCT06013865	Map
TN	Vanderbilt University Medical Center	Nashville37212	NCT03424005	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT05972564	Map
TX	Amarillo Heart Clinical Research Institute, Incorporated	Amarillo79124	NCT06424288	Map
TX	Amarillo Heart Clinical Research Institute, Incorporated	Amarillo79124	NCT06935370	Map
TX	CON-10045 Amarillo, TX Investigational Site	Amarillo79106	NCT06024746	Map
TX	Pharmatex Research	Amarillo79109	NCT06424288	Map
TX	Pharmatex Research	Amarillo79109	NCT06935370	Map
TX	CON-10015 Austin, TX Investigational Site	Austin78705	NCT06024746	Map
TX	Pinnacle Clinical Research - Austin	Austin78757	NCT07064473	Map
TX	Research Management, Inc - Austin	Austin78751	NCT06531824	Map
TX	NextStage Clinical Research	Beaumont77702-1513	NCT06935370	Map
TX	Headlands Research - Brownsville	Brownsville78526	NCT07064473	Map
TX	Javara Inc / Texas Health Care, PLLC	Dallas75230	NCT07064473	Map
TX	North Texas Endocrine Center	Dallas75231	NCT07064473	Map
TX	Soltero Cardiovascular Research Center	Dallas75226	NCT07064473	Map
TX	Southwest Family Medicine Associates	Dallas75235	NCT06424288	Map
TX	Southwest Family Medicine Associates	Dallas75235	NCT06935370	Map
TX	Southwest Family Medicine Associates	Dallas75235	NCT07064473	Map
TX	Texas Health Research and Education Institute	Dallas75231	NCT06424288	Map
TX	Texas Health Research and Education Institute	Dallas75231	NCT06935370	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT06424288	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT07064473	Map
TX	Dallas Nephrology Associates Medical Clinic	DeSoto75115-2011	NCT06531824	Map
TX	Academy Of Diabetes, Thyroid And Endocrine, PA	El Paso79935	NCT06531824	Map
TX	Care United Research	Forney75126	NCT07064473	Map
TX	Diabetes and Thyroid Center of Fort Worth	Fort Worth76132	NCT07064473	Map
TX	Helios CR Inc	Fort Worth76104	NCT06424288	Map
TX	Helios CR Inc - Fort Worth	Fort Worth76104	NCT06935370	Map
TX	Texas Health Physicians Group	Fort Worth76107	NCT07064473	Map
TX	Victorium Clinical Research	Houston77024	NCT07064473	Map
TX	DM Clinical Research Dallas	Irving75061	NCT06935370	Map
TX	Private Practice Leadership, LLC	Katy77493	NCT06424288	Map
TX	Texas Cardiology Research Center PLLC	Kingwood77339	NCT06424288	Map
TX	Epic Clinical Research	Lewisville75057	NCT07064473	Map
TX	DCOL Center for Clinical Research	Longview75605	NCT06424288	Map
TX	DCOL Center for Clinical Research	Longview75605	NCT06935370	Map
TX	P&I Clinical Research, LLC	Lufkin75904	NCT06531824	Map
TX	Texas Institute for Kidney and Endocrine Disorders	Lufkin75904	NCT06531824	Map
TX	North Texas Research Associates	McKinney75071	NCT06424288	Map
TX	North Texas Research Associates	McKinney75071	NCT06935370	Map
TX	Revival Research Institute, LLC - McKinney	McKinney75071	NCT06935370	Map
TX	Texas Institute Of Cardiology	McKinney75071	NCT06424288	Map
TX	Texas Institute Of Cardiology	McKinney75071	NCT06935370	Map
TX	Southern Endocrinology Associates	Mesquite75149	NCT07064473	Map
TX	Renal Specialists of Houston, PA	Pasadena77504-1944	NCT06531824	Map
TX	Accurate Clinical Research, Inc.	Richmond77469	NCT06935370	Map
TX	Endeavor Clinical Trials	San Antonio78240	NCT07064473	Map
TX	IMA Clinical Research San Antonio	San Antonio78229	NCT07064473	Map
TX	Tekton Research-San Antonio-68916	San Antonio78258	NCT07064473	Map
TX	Texas Diabetes Institute - University Health System	San Antonio78207	NCT06229678	Map
TX	Texas Diabetes Institute/UH	San Antonio78229-3900	NCT07053293	Map
TX	Texas Diabetes Institute/UH	San Antonio78229-3900	NCT07053306	Map
TX	Texas Diabetes Institute/UH	San Antonio78229-3900	NCT07053319	Map
TX	Texas Diabetes Institute/UH	San Antonio78229-3900	NCT05960656	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT05057806	Map
TX	Javara Inc. and Privia Medical Group Gulf Coast, PLLC	San Marcos78666	NCT07064473	Map
TX	Consano Clinical Research	Shavano Park78231	NCT07064473	Map
TX	Sherman Clinical Research	Sherman75090	NCT07064473	Map
TX	Javara Inc.-Stephenville-68996	Stephenville76401	NCT07064473	Map
TX	Northwest Heart Center	Tomball77375	NCT06935370	Map
TX	Northwest Houston Heart Center	Tomball77375	NCT07064473	Map
TX	NextStage Clinical Research	Waco76712	NCT06935370	Map
TX	Velocity Clinical Research, Waco	Waco76710	NCT07064473	Map
TX	Texas Valley Clinical Research	Weslaco78596	NCT07064473	Map
UT	Olympus Family Medicine	Salt Lake City84117	NCT07064473	Map
UT	University of Utah Health	Salt Lake City84108	NCT06424288	Map
UT	VA Salt Lake City Health Care System, Salt Lake City, UT	Salt Lake City84148-0001	NCT06625073	Map
UT	Velocity Clinical Research-West Jordan-69043	West Jordan84088	NCT07064473	Map
VA	University of Virginia Health System	Charlottesville22903	NCT06531824	Map
VA	Seven Corners Medical Center	Falls Church22044	NCT07064473	Map
VA	Carient Heart and Vascular	Manassas20109	NCT06424288	Map
VA	Carient Heart and Vascular	Manassas20109	NCT06935370	Map
VA	Carient Heart and Vascular	Manassas20109	NCT07064473	Map
VA	Kidney and Hypertension Specialists, PLLC	Manassas20110	NCT06531824	Map
VA	Tidewater Physicians Multispecialty Group	Newport News23606	NCT06531824	Map
VA	Sentara Norfolk General Hospital	Norfolk23507	NCT06424288	Map
VA	York Clinical Research	Norfolk23504	NCT07064473	Map
VA	Dominion Medical Associates - Downtown	Richmond23219	NCT07064473	Map
VA	Carilion Clinic	Roanoke24014	NCT06935370	Map
VA	Salem VA Medical Center	Salem24153	NCT06531824	Map
VA	Selma Medical Associates, Winchester	Winchester22601	NCT06424288	Map
VA	Selma Medical Associates, Winchester	Winchester22601	NCT07064473	Map
WA	Virginia Mason Medical Center	Seattle98101	NCT06424288	Map
WA	Providence Medical Research Center	Spokane99204	NCT06531824	Map
WA	Universal Research Group, LLC	Tacoma98405	NCT07064473	Map
WV	Frontier Clinical Research, LLC - Morgantown	Morgantown26505	NCT07064473	Map
WI	Clinical Investigation Specialists, Inc.-Kenosha-69111	Kenosha53144	NCT07064473	Map
WI	Drug Research and Analysis Corporation	Madison53717	NCT06424288	Map
WI	ProHealth Care Research Institute and Cardiology Associates	Waukesha53188	NCT06424288	Map
WI	Allegiance Research Specialists	Wauwatosa53226	NCT07064473	Map

Empagliflozin clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	Total
Early P1	7							2	9
P1	7	1		51				5	64
P1/P2	2	1		2					5
P2	16	3	1	27	6	5	4	6	68
P2/P3	4	1		7				4	16
P3	18	3	1	33	3	5	3	12	78
P4	23	5	1	49	4	5	7	22	116
N/A	3	6	1	46		1	3	12	72

Recruiting Empagliflozin clinical trials (101)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT04381936	RECOVERYRandomised Evaluation of COVID-19 Therapy	P3	Pneumonia	70,000	Mar 2020
NCT05501483	DiaSpaxAdipose Tissue Heterogeneity and Its Link to Type 2 Diabetes	N/A	Type 2 Diabetes	60	Feb 2023
NCT07533747	PRECISE-CMDPRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction	P3	Coronary Microvascular Dysfunction (CMD)	100	May 2026
NCT06249932	EMPA-RREDEmpagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease	P4	Heart Failure with Reduced Ejection Fraction	95	Mar 2024
NCT06249945	EMPA-PREDEMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease	P4	Heart Failure With Preserved Ejection Fraction	150	Mar 2024
NCT06642623	ENVELOPA Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients	P4	Diabetes Mellitus, Type 2	2,862	Jan 2024
NCT07175051	EMPA-CKDTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin	P2	Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)	20	Apr 2026
NCT06992440	EmPATHEmpagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension	P2	Pulmonary Arterial Hypertension	78	Jun 2025
NCT06653738	EMPASTONETrial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention	P3	Kidney Stone	400	Jun 2026
NCT03424005	Morpheus-panBCA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	Metastatic Breast Cancer	1,132	Mar 2018
NCT06013865	SEKTREmpagliflozin Treatment in Kidney Transplant Recipients	P4	Kidney Transplant	264	Apr 2024
NCT06625073	Randomized Trial of SGLT2i in Heart Transplant Recipients	P4	Heart Transplant	200	Jan 2026
NCT06745063	EMPAArterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity	P2	Obesity	50	May 2025
NCT07064473	BI 690517EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	P3	Diabetes Mellitus, Type 2	11,800	Jul 2025
NCT07060417	EMPA-CKDVascular Effects of SGLT2i in Non-diabetic CKD	P2	Non-diabetic Chronic Kidney Disease	52	Aug 2026
NCT07322237	DICEDICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis	P4	Cirrhotic Cardiomyopathy	400	Apr 2026
NCT07107945	A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)	P3	Chronic Kidney Disease	120	Dec 2025
NCT06715449	EMPA-ESUSEMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source	P2/P3	Embolic Stroke of Undetermined Source	100	Nov 2024
NCT06506422	ERASE-AgingEmpagliflozin Reversal of Arterial StiffnEss in Aging	P2/P3	Aging	80	Aug 2024
NCT06935370	BI 690517A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart	P3	Heart Failure	4,200	May 2025
NCT06507657	Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure	Early P1	Hypertension	80	Dec 2024
NCT06642272	APPLE TREEA Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record	P4	Diabetes Mellitus, Type 2	17,200	Oct 2024
NCT07228195	SITSGLT2i Therapy in Islet Transplantation (SIT)	P4	Partial Islet Function	40	Jul 2026
NCT06110130	EMPA CKDEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD	P4	Chronic Kidney Diseases	60	Feb 2024
NCT06762314	Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes	P2	Diabetes	105	Jan 2025
NCT06531824	EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)	P3	Kidney Disease, Chronic	11,000	Aug 2024
NCT06424288	A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure	P3	Heart Failure	6,000	Jun 2024
NCT07348484	Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors	—	Chronic Kidney Disease	300	Jan 2026
NCT06955260	EMPA-HEART-3SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure	P3	Congenital Heart Disease	410	May 2025
NCT07304817	COMPARE-VSComparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)	P2	CKD	100	May 2026
NCT06674109	SAVE-CareSAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial	P4	Gout and Hyperuricemia	60	May 2026
NCT03867487	SLIDESGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease	P2	Non-Alcoholic Fatty Liver Disease	40	May 2027
NCT06355310	SHIELDMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease	P2	Non-Alcoholic Fatty Liver Disease	40	Apr 2025
NCT07074418	EMPA[10-20]Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2	P4	Chronic Kidney Diseases	34	Apr 2026
NCT07055282	SGLT2i in Kidney Stones	Early P1	Kidney Stones	32	Nov 2025
NCT06528405	ESS-AKDThe Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease	P2	Acute Kidney Injury	264	Nov 2024
NCT06613854	E-SEMPAEffect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes	P4	Type 2 Diabetes Mellitus (T2DM)	90	Oct 2024
NCT06519448	RedNASHReducing Non-Alcoholic Steatohepatitis	N/A	Non-alcoholic Steatohepatitis	30	Apr 2024
NCT05392764	EMPA-AHFEarly Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure	P3	Acute Heart Failure	444	Sep 2022
NCT07336797	Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy	P2	Metabolic Syndrome	66	Sep 2025
NCT05715814	CANARYmeChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis	P3	Peritoneal Dialysis Complication	20	Sep 2024
NCT07292909	EMPANTINFLAMEffect of Empagliflozin on Inflammation	P4	CAD - Coronary Artery Disease	100	Sep 2025
NCT05028140	PIEMONTEEfficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus	P3	Type II Diabetes	480	Oct 2024
NCT04602754	Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.	P3	Dyslipidemia Associated With Type II Diabetes Mellitus	228	Dec 2023
NCT07146880	Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome	P2	Brugada Syndrome (BrS)	10	Sep 2025
NCT07365358	EMPAGOEvaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients	P4	Diabete Type 2	200	Mar 2026
NCT07155694	Role of Finerenone in African American Veterans With Diabetic Kidney Disease	P4	Diabetic Kidney Disease	30	Sep 2025
NCT05164263	EASEReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study	P4	Type II Diabetes Mellitus	2,000	Apr 2021
NCT06668753	Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	—	Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	114	Nov 2024
NCT07053319	SGLT2i, Pioglitazone, and Ketone Production in T2D	P1	Type 2 Diabetes	64	May 2026
NCT07053306	SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia	P1	Type 2 Diabetes	29	Apr 2025
NCT07053293	SGLT2i, Hepatic Glucose Production, and SNS	Early P1	Type 2 Diabetes	22	Jan 2025
NCT06989723	Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes	P4	Type 2 Diabetes	120	Jan 2025
NCT04670666	Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus	P3	Type 2 Diabetes Mellitus	270	Nov 2024
NCT05960656	SGLTi, Hepatic Glucose Production and Ketogenesis	P1	Type 2 Diabetes	30	Oct 2023
NCT06260059	EmpaCHDEfficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease	P4	Adult Congenital Heart Disease	40	Sep 2024
NCT06729996	PEP-DMPioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus	P2	Pancreatitis, Chronic	40	May 2025
NCT05138575	SAKSGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial	P2	Heart Failure With Preserved Ejection Fraction	53	Jan 2022
NCT07093476	Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin	P3	T2DM	171	Jul 2025
NCT07442006	Glycemic Variability of Combination Therapies in T2DM	P4	Type 2 Diabetes Mellitus (T2DM)	178	Oct 2025
NCT06643442	REDMeDRepurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age	P2	DMD-associated Dilated Cardiomyopathy	12	Oct 2025
NCT05057806	SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan	Early P1	Type2 Diabetes	30	Jan 2021
NCT05879276	EMPASHOCKEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.	P3	Cardiogenic Shock	164	Dec 2024
NCT06229678	Ketones, SGLT2, HFrEF	Early P1	Type2diabetes	71	Jan 2024
NCT06473844	Efficacy of SGLT2 Inhibitors in Adults With Sepsis	N/A	Sepsis	60	Mar 2025
NCT04447911	EMPOWEREffects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia	P4	Hyponatremia	172	Feb 2021
NCT07372040	Add-on Diuretics in Acute Decompensated Heart Failure	P2	Acute Decompensated Heart Failure	66	Feb 2026
NCT06894784	SEMPAA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes	P3	Diabetes Type 1	36	Apr 2025
NCT07472920	EMPA-BDEmpagliflozin Adjunctive Therapy in Bipolar Depression	N/A	Bipolar Disorder	20	Mar 2026
NCT07311551	BMIA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)	P4	Type 2 Diabetes	112	Dec 2025
NCT07065357	TIME-SGLT2Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor	P3	Metabolic Syndrome	160	Aug 2025
NCT06570473	CRAVEFeasibility Trial for a Right Ventricular Failure Platform Trial	P2	Pulmonary Hypertension	30	Jul 2025
NCT06030843	TREAT-CRSThe Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1	P2/P3	Empagliflozin in Cardiorenal Syndrome Type 1	200	Mar 2025
NCT06554301	A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension	P1	Pulmonary Arterial Hypertension	72	Oct 2024
NCT06055452	Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension	P4	Pre-Heart Failure	120	Jan 2024
NCT05669742	Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients	P3	Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics	40	May 2023
NCT05671991	EMPA-PDEffect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease	P4	End Stage Renal Disease on Dialysis	30	Mar 2023
NCT05786443	SEEDSafety and Efficacy of Empagliflozin in Hemodialysis	P2	End Stage Renal Disease	60	Jan 2024
NCT05972564	SADIE2The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function	P1/P2	Obesity	74	Sep 2023
NCT06706791	Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II	P4	Chronic Heart Failure	156	Apr 2025
NCT05610956	Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis	Early P1	Ulcerative Colitis	60	Jan 2023
NCT06483074	EMPIRIC-PDEmpagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients	P2	End Stage Renal Disease on Dialysis	48	Jul 2024
NCT07214818	SGLT2-NSSGLT2 Inhibitors in Adult Primary Nephrotic Syndrome	P2/P3	Nephrotic Syndrome	75	Nov 2025
NCT06024746	CONFIRMATIONA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)	P3	Heart Failure	1,500	Jul 2024
NCT06410352	Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome	P4	Metabolic Syndrome	220	Mar 2024
NCT06430684	SGLT2I-IN-KIDSFeasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease	Early P1	Chronic Kidney Diseases	40	Aug 2024
NCT07452913	Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes	P4	Type 2 Diabetes Mellitus	110	Jan 2026
NCT07038356	EMPA-CONEffects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure	P3	Acute Decompensated Heart Failure (ADHF)	536	Dec 2025
NCT06862739	GLYCO-3PGlycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination	P4	Diabetes Mellitus	800	Oct 2025
NCT07331389	A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin	P1	Overweight Subject	111	Sep 2025
NCT05726032	EMPA LiverEmpagliflozin in Patients With Cirrhosis and Ascites	P2	Cirrhosis	20	Sep 2023
NCT05757791	SGLT2Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)	P2	Major Depressive Disorder	16	Mar 2023
NCT05905965	DEMETEREfficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment	P3	Metabolic Syndrome	200	May 2023
NCT07180745	Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease	P4	Non-alcoholic Fatty Liver Disease NAFLD	400	Nov 2025
NCT06846411	EMPA-FITThe EMPA-FIT Study	P4	Diabetes	46	Jan 2024
NCT06095492	EmLinaRenalEffect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus	N/A	Kidney Transplant; Complications	200	Oct 2023
NCT05553938	EMPA HFEffects of Acute and Chronic Empagliflozin Heart Failure	P1	Heart Failure	60	Aug 2023
NCT06435858	SIDIAShort-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease	P2	Autosomal Dominant Polycystic Kidney Disease	40	Sep 2024
NCT06021145	AIDEffectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes	P4	Type 1 Diabetes	46	Apr 2024
NCT06641128	The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate	P4	Rheumatoid Arthritis (RA)	44	Oct 2024
NCT06578676	To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults	P1	Type 2 Diabetes	56	Jun 2024

Empagliflozin clinical trials by indication

Diabetes Mellitus, Type 2 (51)

NCT	Acronym	Phase	Status	Title
NCT06642623	ENVELOP	P4	recruiting	A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
NCT07064473	BI 690517	P3	recruiting	EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT06642272	APPLE TREE	P4	recruiting	A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
NCT06083675	—	P3	withdrawn	Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
NCT03363464	—	N/A	active not recruiting	Comparative Effectiveness of Empagliflozin in the US
NCT07531108	—	P4	completed	Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
NCT05444153	PIONEER START	P3	withdrawn	Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
NCT05130463	PMS	N/A	completed	Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
+ 43 more, see All trials below.

Type 2 Diabetes (25)

NCT	Acronym	Phase	Status	Title
NCT05501483	DiaSpax	N/A	recruiting	Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
NCT07053319	—	P1	recruiting	SGLT2i, Pioglitazone, and Ketone Production in T2D
NCT07053306	—	P1	recruiting	SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
NCT07053293	—	Early P1	recruiting	SGLT2i, Hepatic Glucose Production, and SNS
NCT06989723	—	P4	recruiting	Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
NCT05960656	—	P1	recruiting	SGLTi, Hepatic Glucose Production and Ketogenesis
NCT07311551	BMI	P4	not yet recruiting	A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
NCT07120828	CYP8B1-SGLT2-T	P4	completed	The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
+ 17 more, see All trials below.

Heart Failure (25)

NCT	Acronym	Phase	Status	Title
NCT06935370	BI 690517	P3	recruiting	A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06424288	—	P3	recruiting	A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT07303556	ICDDTKZ26	N/A	active not recruiting	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
NCT06024746	CONFIRMATION	P3	recruiting	A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
NCT07379788	—	N/A	completed	ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
NCT05553938	EMPA HF	P1	recruiting	Effects of Acute and Chronic Empagliflozin Heart Failure
NCT05584319	EMPAGUM	P4	unknown	EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
NCT05600387	—	P4	unknown	Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
+ 17 more, see All trials below.

Healthy (23)

NCT	Acronym	Phase	Status	Title
NCT07133399	—	P1	completed	A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood
NCT06962826	—	P1	completed	A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food
NCT05956522	—	P1	completed	Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects
NCT05083949	InPedILD®	P1	completed	A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
NCT05132023	—	P1	completed	Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)
NCT03629054	—	P1	completed	This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
NCT03259490	—	P1	completed	This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
NCT02821910	—	P1	completed	Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
+ 15 more, see All trials below.

Type 2 Diabetes Mellitus (19)

NCT	Acronym	Phase	Status	Title
NCT04670666	—	P3	recruiting	Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
NCT05313529	LIGHT-MCI	N/A	active not recruiting	LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
NCT07452913	—	P4	enrolling by invitation	Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
NCT07541456	EMPA-BP	P4	completed	Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
NCT04603508	—	P3	unknown	Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
NCT06759922	—	P4	completed	Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
NCT05254002	CONFIDENCE	P2	completed	A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
NCT05073692	ON TARGET DM	N/A	completed	Comparison of Type 2 Diabetes Pharmacotherapy Regimens
+ 11 more, see All trials below.

Diabetes Mellitus (11)

NCT	Acronym	Phase	Status	Title
NCT06862739	GLYCO-3P	P4	recruiting	Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
NCT06098625	EmLina Renal	N/A	unknown	Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus
NCT06915870	—	N/A	completed	Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
NCT06952231	—	P3	completed	Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus
NCT03877406	—	P4	unknown	Effect of Empagliflozin on Body Composition and Ketones
NCT03208465	ELITE	P4	completed	Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
NCT04143321	—	P4	completed	Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina
NCT03462069	—	P2	completed	Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
+ 3 more, see All trials below.

Type 2 Diabetes Mellitus (T2DM) (7)

NCT	Acronym	Phase	Status	Title
NCT06613854	E-SEMPA	P4	recruiting	Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
NCT07442006	—	P4	recruiting	Glycemic Variability of Combination Therapies in T2DM
NCT07372118	—	P1	completed	Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition
NCT07266766	—	P1	completed	Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
NCT07213895	—	P1	completed	Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
NCT07039890	—	P1	completed	To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
NCT06932159	—	P1	completed	Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

Diabetes Mellitus Type 2 (7)

NCT	Acronym	Phase	Status	Title
NCT06851962	EPHIC-DIA2	P4	active not recruiting	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT06823856	—	P1	completed	Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
NCT06792968	—	P1	completed	Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
NCT06766500	—	P1	completed	Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
NCT02752113	ELMI	P3	completed	Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
NCT02728453	EMPATROPHY	P4	terminated	SGLT2 Inhibition and Left Ventricular Mass
NCT02471963	—	P3	completed	Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Obesity (6)

NCT	Acronym	Phase	Status	Title
NCT06745063	EMPA	P2	recruiting	Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
NCT05885074	—	P2	withdrawn	Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors
NCT05972564	SADIE2	P1/P2	recruiting	The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
NCT05042973	—	P2	completed	The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT04907214	—	P1/P2	completed	SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
NCT04143581	EMPATHY	P2	withdrawn	SGLT2 Inhibitors in Glomerular Hyperfiltration

Type2 Diabetes (6)

NCT	Acronym	Phase	Status	Title
NCT05057806	—	Early P1	recruiting	SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
NCT04203927	EJB051	Early P1	unknown	Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
NCT03748810	—	N/A	completed	Head-to-head Comparison of Empagliflozin and Dapagliflozin
NCT03766724	—	P1	completed	Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
NCT02964715	—	P4	unknown	The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
NCT03458715	—	P4	unknown	The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Metabolic Syndrome (5)

NCT	Acronym	Phase	Status	Title
NCT07336797	—	P2	recruiting	Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
NCT07065357	TIME-SGLT2	P3	enrolling by invitation	Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor
NCT06410352	—	P4	recruiting	Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
NCT05905965	DEMETER	P3	recruiting	Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
NCT03912909	EMPA-SNS	P4	unknown	Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans

Diabetes (5)

NCT	Acronym	Phase	Status	Title
NCT06762314	—	P2	recruiting	Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06846411	EMPA-FIT	P4	recruiting	The EMPA-FIT Study
NCT04215536	—	N/A	completed	Replication of the EMPAREG Diabetes Trial in Healthcare Claims
NCT02998970	EMPA-HEART	P4	unknown	Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
NCT02863328	PIONEER 2	P3	completed	Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 1 (5)

NCT	Acronym	Phase	Status	Title
NCT02632747	—	P2	completed	Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
NCT02414958	EASE-2	P3	completed	Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
NCT02580591	EASE-3	P3	completed	Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
NCT02702011	—	P2	completed	Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
NCT01969747	—	P2	completed	Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Non-Alcoholic Fatty Liver Disease (4)

NCT	Acronym	Phase	Status	Title
NCT03867487	SLIDE	P2	not yet recruiting	SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
NCT06355310	SHIELD	P2	recruiting	Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
NCT05942963	—	P4	unknown	Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
NCT05946148	NAMELS-18	N/A	completed	Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

Chronic Kidney Disease (4)

NCT	Acronym	Phase	Status	Title
NCT07107945	—	P3	recruiting	A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07348484	—	N/A	not yet recruiting	Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
NCT06926660	—	P2	active not recruiting	A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT03594110	—	P3	completed	EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Diabetic Kidney Disease (4)

NCT	Acronym	Phase	Status	Title
NCT07155694	—	P4	not yet recruiting	Role of Finerenone in African American Veterans With Diabetic Kidney Disease
NCT06187493	—	N/A	unknown	Treatment of Patients With Diabetic Kidney Disease
NCT03173963	—	P3	withdrawn	Empaglifozin in Early Diabetic Kidney Disease
NCT03078101	EMPRA	P2	completed	EMPRA (EMPagliflozin and RAs in Kidney Disease)

Type2 Diabetes Mellitus (4)

NCT	Acronym	Phase	Status	Title
NCT06180109	—	P1	completed	Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition
NCT03437330	—	P4	withdrawn	Empagliflozin Effect on Glucose Toxicity
NCT03151343	SIMPLE	P3	completed	SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk
NCT02964572	—	N/A	completed	Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Chronic Kidney Diseases (3)

NCT	Acronym	Phase	Status	Title
NCT06110130	EMPA CKD	P4	recruiting	Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
NCT07074418	EMPA[10-20]	P4	not yet recruiting	Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
NCT06430684	SGLT2I-IN-KIDS	Early P1	recruiting	Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

Acute Decompensated Heart Failure (3)

NCT	Acronym	Phase	Status	Title
NCT07372040	—	P2	recruiting	Add-on Diuretics in Acute Decompensated Heart Failure
NCT05776043	EMPATHY	P3	unknown	Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
NCT04049045	EMPAG-HF	P2	completed	Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

Healthy Volunteers (3)

NCT	Acronym	Phase	Status	Title
NCT07102719	—	P1	completed	Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
NCT06889350	—	P1	completed	Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
NCT06339788	—	P1	completed	Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

T2DM (3)

NCT	Acronym	Phase	Status	Title
NCT07093476	—	P3	recruiting	Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
NCT06571591	CT-L03	P3	completed	Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
NCT05681273	—	P1	completed	Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Chronic Heart Failure (3)

NCT	Acronym	Phase	Status	Title
NCT06706791	—	P4	recruiting	Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
NCT05364190	The CANA -AHF	P3	completed	Canagliflozin in Patients With Acute Decompansted Heart Failure
NCT03128528	ELSI	P2	completed	Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

Hypertension (3)

NCT	Acronym	Phase	Status	Title
NCT06507657	—	Early P1	recruiting	Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
NCT01001962	PREHYPD	P4	unknown	Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
NCT04203914	EMPHYT	P4	completed	Short Term Effect of Empagliflozin in Hypertension

Diabete Mellitus (3)

NCT	Acronym	Phase	Status	Title
NCT07169981	EMPA-DMMI	P2	completed	Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
NCT07367555	SGLT-2	P1	completed	Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients
NCT07247656	—	P4	completed	The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

Heart Failure With Preserved Ejection Fraction (3)

NCT	Acronym	Phase	Status	Title
NCT06249945	EMPA-PRED	P4	recruiting	EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
NCT05138575	SAK	P2	recruiting	SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
NCT05129722	—	P4	terminated	Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial

Kidney Transplant; Complications (3)

NCT	Acronym	Phase	Status	Title
NCT04906213	CREST-KT	P2	terminated	CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
NCT06095492	EmLinaRenal	N/A	recruiting	Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
NCT04918407	—	N/A	completed	Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Acute Heart Failure (3)

NCT	Acronym	Phase	Status	Title
NCT05392764	EMPA-AHF	P3	recruiting	Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05305495	DRIP-AHF-1	P4	completed	Empagliflozin in Acute Heart Failure
NCT05556044	EMPA	P3	unknown	Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction

Heart Failure With Reduced Ejection Fraction (3)

NCT	Acronym	Phase	Status	Title
NCT05778084	—	P4	unknown	Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction
NCT06632561	HFrEF	P4	completed	Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
NCT03198585	Empire HF	P2	completed	Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

Postprandial Hypoglycemia (3)

NCT	Acronym	Phase	Status	Title
NCT05174507	Hypo-PrEA	P2	withdrawn	Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
NCT05036317	EmpHy	P3	terminated	Empagliflozin for the Treatment of Postprandial Hypoglycemia
NCT03200782	Hypo-BEAR	N/A	completed	Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Diabete Type 2 (2)

NCT	Acronym	Phase	Status	Title
NCT07365358	EMPAGO	P4	not yet recruiting	Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
NCT05359341	—	N/A	completed	Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Pulmonary Arterial Hypertension (2)

NCT	Acronym	Phase	Status	Title
NCT06992440	EmPATH	P2	enrolling by invitation	Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
NCT06554301	—	P1	recruiting	A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Kidney Stone (2)

NCT	Acronym	Phase	Status	Title
NCT06653738	EMPASTONE	P3	not yet recruiting	Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
NCT04911660	SWEETSTONE	P2	completed	Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers

Congenital Heart Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06955260	EMPA-HEART-3	P3	not yet recruiting	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT05580510	—	P2/P3	unknown	" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Acute Kidney Injury (2)

NCT	Acronym	Phase	Status	Title
NCT06528405	ESS-AKD	P2	recruiting	The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
NCT06825156	MERCURI	P4	completed	Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors

Kidney Disease, Chronic (2)

NCT	Acronym	Phase	Status	Title
NCT06531824	—	P3	recruiting	EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT05182840	—	P2	completed	A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

End Stage Renal Disease on Dialysis (2)

NCT	Acronym	Phase	Status	Title
NCT05671991	EMPA-PD	P4	recruiting	Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
NCT06483074	EMPIRIC-PD	P2	recruiting	Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients

Type 1 Diabetes (2)

NCT	Acronym	Phase	Status	Title
NCT06021145	AID	P4	recruiting	Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes
NCT04201496	CiQ-SGLT2	P1	completed	SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

End Stage Renal Disease (2)

NCT	Acronym	Phase	Status	Title
NCT05786443	SEED	P2	recruiting	Safety and Efficacy of Empagliflozin in Hemodialysis
NCT03713190	ESRD	P2	completed	Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

Polycystic Ovary Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT06140108	—	P2/P3	completed	Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity
NCT03008551	—	P2/P3	completed	Empagliflozin vs Metformin in PCOS

Coronary Artery Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06313008	—	N/A	completed	Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
NCT04497792	SAFARY	P4	completed	Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

Glycogen Storage Disease Type IB (2)

NCT	Acronym	Phase	Status	Title
NCT05960617	—	P2	withdrawn	Efficacy and Safety of Empagliflozin in GSD-Ib Patients
NCT04986735	—	N/A	unknown	Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin

Diabetic Nephropathy Type 2 (2)

NCT	Acronym	Phase	Status	Title
NCT05373004	SGLT2i VS ACEi	P2/P3	unknown	Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
NCT03504566	ROTATE-2	P4	withdrawn	Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Ulcerative Colitis (2)

NCT	Acronym	Phase	Status	Title
NCT05610956	—	Early P1	recruiting	Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
NCT05058417	—	P2	withdrawn	Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Diabetic Nephropathies (2)

NCT	Acronym	Phase	Status	Title
NCT05638880	—	P2	completed	Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
NCT03933956	(MEDiaN)	P3	terminated	Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)

PreDiabetes (2)

NCT	Acronym	Phase	Status	Title
NCT05426525	—	P4	active not recruiting	Use of Empagliflozin to Treat Prediabetes
NCT03227484	—	P2	completed	Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

Myocardial Infarction (2)

NCT	Acronym	Phase	Status	Title
NCT05020704	EMPRESS-MI	P3	unknown	EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
NCT04509674	EMPACT-MI	P3	completed	EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Hypertrophic Cardiomyopathy (2)

NCT	Acronym	Phase	Status	Title
NCT05182658	EMPA-REPAIR	P3	active not recruiting	Empagliflozin in Hypertrophic Cardiomyopathy
NCT06401343	—	P4	unknown	Use of SGLT2i in noHCM With HFpEF

Cardiovascular Diseases (2)

NCT	Acronym	Phase	Status	Title
NCT04461041	EMPA-HEART 2	P4	completed	Empagliflozin and Cardiac Remodelling in People Without Diabetes
NCT03485222	EMPA-TROPISM	P4	completed	Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

Type II Diabetes Mellitus (2)

NCT	Acronym	Phase	Status	Title
NCT05164263	EASE	P4	recruiting	Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
NCT04665284	SAFE-PAK	P4	completed	Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Insulin Resistance - Type A (2)

NCT	Acronym	Phase	Status	Title
NCT04221152	EMPIRE-02	P3	unknown	A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
NCT04018365	EMPIRE-01	P3	unknown	A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Diabetes Mellitus, Type II (2)

NCT	Acronym	Phase	Status	Title
NCT02985242	—	P4	terminated	Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
NCT02854748	—	P1	unknown	Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Coronary Microvascular Dysfunction (CMD) (1)

NCT	Acronym	Phase	Status	Title
NCT07533747	PRECISE-CMD	P3	not yet recruiting	PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction

Partial Islet Function (1)

NCT	Acronym	Phase	Status	Title
NCT07228195	SIT	P4	not yet recruiting	SGLT2i Therapy in Islet Transplantation (SIT)

Gout and Hyperuricemia (1)

NCT	Acronym	Phase	Status	Title
NCT06674109	SAVE-Care	P4	recruiting	SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

CKD (1)

NCT	Acronym	Phase	Status	Title
NCT07304817	COMPARE-VS	P2	recruiting	Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

Non-diabetic Chronic Kidney Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07060417	EMPA-CKD	P2	not yet recruiting	Vascular Effects of SGLT2i in Non-diabetic CKD

Bipolar Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT07472920	EMPA-BD	N/A	not yet recruiting	Empagliflozin Adjunctive Therapy in Bipolar Depression

Heart Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT06625073	—	P4	recruiting	Randomized Trial of SGLT2i in Heart Transplant Recipients

Cirrhotic Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT07322237	DICE	P4	recruiting	DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) (1)

NCT	Acronym	Phase	Status	Title
NCT07175051	EMPA-CKD	P2	recruiting	Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Acute Decompensated Heart Failure (ADHF) (1)

NCT	Acronym	Phase	Status	Title
NCT07038356	EMPA-CON	P3	recruiting	Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

Kidney Stones (1)

NCT	Acronym	Phase	Status	Title
NCT07055282	—	Early P1	recruiting	SGLT2i in Kidney Stones

Nephrotic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT07214818	SGLT2-NS	P2/P3	recruiting	SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

Non-alcoholic Fatty Liver Disease NAFLD (1)

NCT	Acronym	Phase	Status	Title
NCT07180745	—	P4	not yet recruiting	Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

DMD-associated Dilated Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT06643442	REDMeD	P2	not yet recruiting	Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

Overweight Subject (1)

NCT	Acronym	Phase	Status	Title
NCT07331389	—	P1	recruiting	A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Brugada Syndrome (BrS) (1)

NCT	Acronym	Phase	Status	Title
NCT07146880	—	P2	not yet recruiting	Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome

CAD - Coronary Artery Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07292909	EMPANTINFLAM	P4	recruiting	Effect of Empagliflozin on Inflammation

Pulmonary Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT06570473	CRAVE	P2	recruiting	Feasibility Trial for a Right Ventricular Failure Platform Trial

Pancreatitis, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT06729996	PEP-DM	P2	recruiting	Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

Diabetes Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT06894784	SEMPA	P3	recruiting	A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

HER2-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06844669	HER2HEART-US	P2	terminated	HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Sepsis (1)

NCT	Acronym	Phase	Status	Title
NCT06473844	—	N/A	recruiting	Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Empagliflozin in Cardiorenal Syndrome Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT06030843	TREAT-CRS	P2/P3	recruiting	The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Thrombosis (1)

NCT	Acronym	Phase	Status	Title
NCT06618976	SOTATHROMBUS	P4	completed	Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

Renal Cell Carcinoma (Kidney Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT06818305	EmFin-Nx	P2	terminated	Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

Cardiogenic Shock (1)

NCT	Acronym	Phase	Status	Title
NCT05879276	EMPASHOCK	P3	recruiting	Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Prediabetes (1)

NCT	Acronym	Phase	Status	Title
NCT06828731	PREVNT	P1	completed	Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Bioequivalance (1)

NCT	Acronym	Phase	Status	Title
NCT07479108	EB-24-003	N/A	completed	Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

Embolic Stroke of Undetermined Source (1)

NCT	Acronym	Phase	Status	Title
NCT06715449	EMPA-ESUS	P2/P3	recruiting	EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy (1)

NCT	Acronym	Phase	Status	Title
NCT06668753	—	N/A	not yet recruiting	Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

Rheumatoid Arthritis (RA) (1)

NCT	Acronym	Phase	Status	Title
NCT06641128	—	P4	not yet recruiting	The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

Type II Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT05028140	PIEMONTE	P3	recruiting	Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Adult Congenital Heart Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06260059	EmpaCHD	P4	recruiting	Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

Peritoneal Dialysis Complication (1)

NCT	Acronym	Phase	Status	Title
NCT05715814	CANARY	P3	recruiting	meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Autosomal Dominant Polycystic Kidney Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06435858	SIDIA	P2	recruiting	Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

STEMI (1)

NCT	Acronym	Phase	Status	Title
NCT06342141	EMPA-PCI	P2	active not recruiting	Empagliflozin for No-reflow Phenomenon in PCI for STEMI

Aging (1)

NCT	Acronym	Phase	Status	Title
NCT06506422	ERASE-Aging	P2/P3	recruiting	Empagliflozin Reversal of Arterial StiffnEss in Aging

Diabetes Mellitus Type 2 With Proteinuria (1)

NCT	Acronym	Phase	Status	Title
NCT06094920	Optimize@Home	P4	completed	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Healthy Volunteer (1)

NCT	Acronym	Phase	Status	Title
NCT06337409	—	P1	unknown	Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Autosomal Dominant Polycystic Kidney (1)

NCT	Acronym	Phase	Status	Title
NCT06391450	EMPA-PKD	P4	active not recruiting	Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Myocardial Suppression (1)

NCT	Acronym	Phase	Status	Title
NCT06350903	SWEET-HEART	N/A	completed	Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging

Moderate Aortic Valve Stenosis (1)

NCT	Acronym	Phase	Status	Title
NCT06469645	—	P2/P3	unknown	The Role of SGLT2i in Management of Moderate AS

Healthy Vollunteer (1)

NCT	Acronym	Phase	Status	Title
NCT06308679	—	P1	unknown	A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Kidney Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT06013865	SEKTR	P4	recruiting	Empagliflozin Treatment in Kidney Transplant Recipients

Non-alcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT06519448	RedNASH	N/A	enrolling by invitation	Reducing Non-Alcoholic Steatohepatitis

Heart Failure with Reduced Ejection Fraction (1)

NCT	Acronym	Phase	Status	Title
NCT06249932	EMPA-RRED	P4	recruiting	Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease

Healthy Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT06232239	—	P1	unknown	Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Aortic Valve Stenosis (1)

NCT	Acronym	Phase	Status	Title
NCT06171802	EMPAVR	P4	completed	EMPagliflozin After Aortic Valve Replacement

Type2diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT06229678	—	Early P1	recruiting	Ketones, SGLT2, HFrEF

Pre-Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT06055452	—	P4	recruiting	Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Cystic Fibrosis-related Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT06149793	—	P2/P3	active not recruiting	SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Genetic Polymorphisms (1)

NCT	Acronym	Phase	Status	Title
NCT06201000	—	N/A	unknown	Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Dyslipidemia Associated With Type II Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT04602754	—	P3	recruiting	Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Glucose Metabolism Disorders (1)

NCT	Acronym	Phase	Status	Title
NCT06145360	OAD	P4	completed	Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Metabolic-associated Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05140694	—	P4	unknown	Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06103279	—	P2/P3	unknown	Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Hematocrit Change (1)

NCT	Acronym	Phase	Status	Title
NCT06284850	—	N/A	unknown	Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Post-operative Atrial Fibrillation (1)

NCT	Acronym	Phase	Status	Title
NCT06124937	EMPOAF	P3	unknown	Empagliflozin to Prevent Post-Operative Atrial Fibrillation

Kidney Failure, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT05687058	—	P1/P2	active not recruiting	Empagliflozin in ESKD - A Feasibility Study

Cardiotoxicity (1)

NCT	Acronym	Phase	Status	Title
NCT05271162	EMPACT	P3	active not recruiting	Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

Cirrhosis (1)

NCT	Acronym	Phase	Status	Title
NCT05726032	EMPA Liver	P2	recruiting	Empagliflozin in Patients With Cirrhosis and Ascites

Hypertension Associated (1)

NCT	Acronym	Phase	Status	Title
NCT04970108	EGITO	P3	withdrawn	Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

Obstructive Sleep Apnea (OSA) (1)

NCT	Acronym	Phase	Status	Title
NCT07556094	HF(L)OSA	N/A	completed	Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.

Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics (1)

NCT	Acronym	Phase	Status	Title
NCT05669742	—	P3	recruiting	Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05694923	Fatty liver	N/A	completed	Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment

End-stage Kidney Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05614115	—	P1	completed	Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Major Depressive Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT05757791	SGLT2	P2	recruiting	Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Congestive Heart Failure (CHF) (1)

NCT	Acronym	Phase	Status	Title
NCT06683053	ADDEMFEP	P3	active not recruiting	Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

Idiopathic Pulmonary Arterial Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT05493371	Emphower PoC	P2	completed	Empagliflozin in Pulmonary Arterial Hypertension

Stable Angina (1)

NCT	Acronym	Phase	Status	Title
NCT05911724	—	N/A	completed	Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Non Alcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT05605158	—	P3	unknown	Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Polycystic Kidney, Autosomal Dominant (1)

NCT	Acronym	Phase	Status	Title
NCT05510115	—	P2	active not recruiting	Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

Epilepsy (1)

NCT	Acronym	Phase	Status	Title
NCT05512130	—	Early P1	unknown	Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy

Empagliflozin in Post AKI Stage 2-3 (1)

NCT	Acronym	Phase	Status	Title
NCT05360615	—	P1	active not recruiting	The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

NASH - Nonalcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT05232071	LEGEND	P2	completed	Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Liver Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT05282121	NASH	P2	terminated	A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Maturity-Onset Diabetes of the Young, Type 3 (1)

NCT	Acronym	Phase	Status	Title
NCT05417646	MOD3ST-CLAMP	N/A	completed	Impact of SGLT2 on Glucosuria in HNF1A-MODY

Ascites Hepatic (1)

NCT	Acronym	Phase	Status	Title
NCT05430243	—	P2/P3	completed	Empagliflozin as a Novel Therapy in Refractory Ascites

Transthyretin Amyloid Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT05233163	—	P4	completed	SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Pharmacogenomic (1)

NCT	Acronym	Phase	Status	Title
NCT05036421	UGT	P3	completed	Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Diabetic Neuropathy Peripheral (1)

NCT	Acronym	Phase	Status	Title
NCT05977465	—	P1/P2	completed	Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Chronic Hepatitis b (1)

NCT	Acronym	Phase	Status	Title
NCT05147090	—	P4	active not recruiting	Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

Renal Insufficiency, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT05373680	—	P2/P3	completed	Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

Endothelial Dysfunction (1)

NCT	Acronym	Phase	Status	Title
NCT05857085	ENDIS	P4	completed	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

Polycystic Ovary Syndrome (PCOS) (1)

NCT	Acronym	Phase	Status	Title
NCT05200793	—	P4	unknown	Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Dumping Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05057819	—	P4	completed	Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Crohn's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05078879	—	P1	completed	Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Liver Cirrhosis (1)

NCT	Acronym	Phase	Status	Title
NCT05013502	DRAin-Em 01	P1	completed	Empagliflozin in Diuretic Refractory Ascites

Heart Failure with Preserved Ejection Fraction (1)

NCT	Acronym	Phase	Status	Title
NCT05139472	—	P4	completed	Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

Atrial Fibrillation (1)

NCT	Acronym	Phase	Status	Title
NCT04583813	EMPA-AF	P4	unknown	Empagliflozin and Atrial Fibrillation Treatment

Mild Cognitive Impairment (1)

NCT	Acronym	Phase	Status	Title
NCT05081219	—	P2	completed	SNIFF - Combo INI+EMPA Trial

Glucose 6 Phosphatase Deficiency (1)

NCT	Acronym	Phase	Status	Title
NCT04930627	EMPAtia	P2	unknown	Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia

type1diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT04917692	—	P4	withdrawn	Empagliflozin in Adolescent Diabetes

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney (1)

NCT	Acronym	Phase	Status	Title
NCT04853615	—	N/A	unknown	SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Pharmacokinetic Parameters (1)

NCT	Acronym	Phase	Status	Title
NCT05229796	—	N/A	completed	Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Tricuspid Regurgitation (1)

NCT	Acronym	Phase	Status	Title
NCT04345796	PROVE	P3	completed	Pharmacological Reduction of Right Ventricular Enlargement

Impaired Glucose Tolerance (1)

NCT	Acronym	Phase	Status	Title
NCT04662866	DIASA3	P2	unknown	Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose

Hyponatremia (1)

NCT	Acronym	Phase	Status	Title
NCT04447911	EMPOWER	P4	recruiting	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Non-alcoholic Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04642261	—	P4	completed	Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

NASH (1)

NCT	Acronym	Phase	Status	Title
NCT04702490	—	P2	unknown	Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Diabetes Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT04910178	—	P4	completed	Follow-up of NAFLD Patients With MRI-PDFF

Acromegaly (1)

NCT	Acronym	Phase	Status	Title
NCT04520646	—	N/A	unknown	A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Diabetes Mellitus Type 2 Without Complication (1)

NCT	Acronym	Phase	Status	Title
NCT05109949	—	P3	unknown	Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04381936	RECOVERY	P3	recruiting	Randomised Evaluation of COVID-19 Therapy

Glomerulonephritis (1)

NCT	Acronym	Phase	Status	Title
NCT05283057	—	P3	completed	Empagliflozin in Patients With Glomerulonephritis

Diabetic Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT04215445	—	P4	unknown	Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Type 2 Diabetes With Renal Manifestations (1)

NCT	Acronym	Phase	Status	Title
NCT04061200	EmpaSema	P4	unknown	Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

Prediabetic State (1)

NCT	Acronym	Phase	Status	Title
NCT04131582	4T	P3	unknown	Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes

Type1 Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03979352	CLASS17	P3	completed	Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting

Glycogen Storage Disease Type I (1)

NCT	Acronym	Phase	Status	Title
NCT04138251	GLYCO-1B	P2	unknown	Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Patients (1)

NCT	Acronym	Phase	Status	Title
NCT03790787	—	P1	completed	Drug Interaction Study Between Dorzagliatin and Empagliflozin

Diabetes After Total Pancreatectomy (1)

NCT	Acronym	Phase	Status	Title
NCT04061473	Px-Meal	N/A	completed	Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion

Empaglifozin (1)

NCT	Acronym	Phase	Status	Title
NCT03852901	—	P1	completed	Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Heart Failure, Diastolic (1)

NCT	Acronym	Phase	Status	Title
NCT03753087	—	P4	completed	Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

Chronic Kidney Disease stage3 (1)

NCT	Acronym	Phase	Status	Title
NCT04961931	—	N/A	unknown	Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03646292	—	P4	completed	Antidiabetic Drugs for Steatotic Liver Disease

Reperfusion Injury, Myocardial (1)

NCT	Acronym	Phase	Status	Title
NCT03591991	—	N/A	unknown	Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI

New Onset Diabetes After Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT03642184	—	P4	terminated	Efficacy and Safety of Empagliflozin in NODAT

Gestational Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT03215069	EMPA post-GDM	P3	completed	Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes

Hepatic Glucose Metabolism (1)

NCT	Acronym	Phase	Status	Title
NCT03193684	—	P4	completed	Empagliflozin and Hepatic Glucose Metabolism

Type1diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT03510000	CLASS15	N/A	completed	Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03424005	Morpheus-panBC	P1/P2	recruiting	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Vascular Stiffness (1)

NCT	Acronym	Phase	Status	Title
NCT03639545	—	P4	unknown	The Effects of Empagliflozin on Arterial Wall Characteristics

Heart Failure Acute (1)

NCT	Acronym	Phase	Status	Title
NCT03200860	EMPA-RESPONSE	P2	completed	Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure

SIAD - Syndrome of Inappropriate Antidiuresis (1)

NCT	Acronym	Phase	Status	Title
NCT03202667	SANDx	P2/P3	completed	Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

SGLT-2 Inhibitors (1)

NCT	Acronym	Phase	Status	Title
NCT02768220	—	P4	withdrawn	The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes Mellitus and Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT03152552	—	P2	terminated	A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Acute Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT03087773	EMMY	P3	completed	Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Diabetes Mellitus Type 2 (T2DM) (1)

NCT	Acronym	Phase	Status	Title
NCT03132181	EMPA	P2	completed	Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

Nephropathy (1)

NCT	Acronym	Phase	Status	Title
NCT03093103	EMPA-REIN	P2	completed	Empagliflozin and Renal Oxygenation in Healthy Volunteers

Nocturnal Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT03050229	—	P4	completed	SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Posttransplant Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03113110	EMPTRA-DM	P2	completed	Empagliflozin in Post-Transplantation Diabetes Mellitus

SIADH (1)

NCT	Acronym	Phase	Status	Title
NCT02874807	SAND	P2/P3	completed	Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Non Alcoholic Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02686476	E-LIFT	N/A	completed	Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Obesity, Visceral (1)

NCT	Acronym	Phase	Status	Title
NCT02833415	—	P4	completed	Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Inappropriate ADH Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT02729766	DIVE	P2/P3	completed	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Acute Myocardial Infarction (AMI) (1)

NCT	Acronym	Phase	Status	Title
NCT07198191	SGLT2i-AMI	N/A	active not recruiting	SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Empagliflozin pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
EMPA-RRED	NCT06249932	P4	recruiting	Heart Failure with Reduced Ejection Fraction	95	PMID 30296931
EMPA-PRED	NCT06249945	P4	recruiting	Heart Failure With Preserved Ejection Fraction	150	PMID 40855136
ENVELOP	NCT06642623	P4	recruiting	Diabetes Mellitus, Type 2	2,862	—
SEKTR	NCT06013865	P4	recruiting	Kidney Transplant	264	—
DICE	NCT07322237	P4	recruiting	Cirrhotic Cardiomyopathy	400	—
APPLE TREE	NCT06642272	P4	recruiting	Diabetes Mellitus, Type 2	17,200	—
SIT	NCT07228195	P4	not yet recruiting	Partial Islet Function	40	—
EMPA CKD	NCT06110130	P4	recruiting	Chronic Kidney Diseases	60	—
SAVE-Care	NCT06674109	P4	recruiting	Gout and Hyperuricemia	60	—
EMPA[10-20]	NCT07074418	P4	not yet recruiting	Chronic Kidney Diseases	34	—
E-SEMPA	NCT06613854	P4	recruiting	Type 2 Diabetes Mellitus (T2DM)	90	—
EMPANTINFLAM	NCT07292909	P4	recruiting	CAD - Coronary Artery Disease	100	—
EMPAGO	NCT07365358	P4	not yet recruiting	Diabete Type 2	200	—
EASE	NCT05164263	P4	recruiting	Type II Diabetes Mellitus	2,000	PMID 24795251
EmpaCHD	NCT06260059	P4	recruiting	Adult Congenital Heart Disease	40	—
EMPA-PKD	NCT06391450	P4	active not recruiting	Autosomal Dominant Polycystic Kidney	44	PMID 39675824
EMPOWER	NCT04447911	P4	recruiting	Hyponatremia	172	—
BMI	NCT07311551	P4	not yet recruiting	Type 2 Diabetes	112	—
EMPA-PD	NCT05671991	P4	recruiting	End Stage Renal Disease on Dialysis	30	—
GLYCO-3P	NCT06862739	P4	recruiting	Diabetes Mellitus	800	—
EPHIC-DIA2	NCT06851962	P4	active not recruiting	Diabetes Mellitus Type 2	504	—
EMPAVR	NCT06171802	P4	completed	Aortic Valve Stenosis	206	PMID 41903746
CYP8B1-SGLT2-T	NCT07120828	P4	completed	Type 2 Diabetes	260	PMID 32855502
DRIP-AHF-1	NCT05305495	P4	completed	Acute Heart Failure	25	—
SOTATHROMBUS	NCT06618976	P4	completed	Thrombosis	17	PMID 40748666
EMPA-FIT	NCT06846411	P4	recruiting	Diabetes	46	—
COMBAT_T2_NASH	NCT04639414	P4	active not recruiting	Type 2 Diabetes	192	—
EMPA-BP	NCT07541456	P4	completed	Type 2 Diabetes Mellitus	300	—
EMPAGUM	NCT05584319	P4	unknown	Heart Failure	100	—
Optimize@Home	NCT06094920	P4	completed	Diabetes Mellitus Type 2 With Proteinuria	12	—
AID	NCT06021145	P4	recruiting	Type 1 Diabetes	46	—
EMPA-SNS	NCT03912909	P4	unknown	Metabolic Syndrome	30	PMID 9562349
EMPA-AF	NCT04583813	P4	unknown	Atrial Fibrillation	400	—
EMPATHYHEART	NCT04117763	P4	completed	Diabetes Mellitus, Type 2	90	—
OAD	NCT06145360	P4	completed	Glucose Metabolism Disorders	150	—
POST-CABGDM	NCT04523064	P4	completed	Diabetes Mellitus, Type 2	155	—
GOLDEN-AGE	NCT04796428	P4	unknown	Diabetes Mellitus, Type 2	1,167	—
MERCURI	NCT06825156	P4	completed	Acute Kidney Injury	60	—
ENDIS	NCT05857085	P4	completed	Endothelial Dysfunction	90	—
SAFE-PCI	NCT05037695	P4	unknown	Diabetes Mellitus, Type 2	40	PMID 37365618
EMPA-HEART 2	NCT04461041	P4	completed	Cardiovascular Diseases	169	PMID 36335517
HFrEF	NCT06632561	P4	completed	Heart Failure With Reduced Ejection Fraction	74	—
REGROUP	NCT04243850	P4	withdrawn	Diabetes Mellitus, Type 2	0	—
FIORE	NCT04183868	P4	completed	Type 2 Diabetes	26	PMID 15249353
RECOLAR	NCT04238702	P4	completed	Diabetes Mellitus, Type 2	24	PMID 38682786
UREX	NCT05210517	P4	completed	Type 2 Diabetes	10	PMID 35322793
EmpaSema	NCT04061200	P4	unknown	Type 2 Diabetes With Renal Manifestations	80	PMID 39963952
SAFE-PAK	NCT04665284	P4	completed	Type II Diabetes Mellitus	244	PMID 36443769
EmDia	NCT02932436	P4	completed	Diabetes Mellitus, Type 2	144	PMID 36763159
ERA-HF	NCT03271879	P4	unknown	Heart Failure	128	—
SUGAR-DM-HF	NCT03485092	P4	completed	Heart Failure	105	—
EMBRACE-HF	NCT03030222	P4	completed	Heart Failure	65	PMID 33550815
EMPA-TROPISM	NCT03485222	P4	completed	Cardiovascular Diseases	84	PMID 33197559
PREHYPD	NCT01001962	P4	unknown	Hypertension	1,054	PMID 32501595
SAFARY	NCT04497792	P4	completed	Coronary Artery Disease	40	—
ELITE	NCT03208465	P4	completed	Diabetes Mellitus	100	PMID 34397987
SEESAW	NCT02798744	P4	completed	Diabetes Mellitus, Type 2	68	PMID 35441435
ROTATE-2	NCT03504566	P4	withdrawn	Diabetic Nephropathy Type 2	0	—
RECEDE-CHF	NCT03226457	P4	completed	Heart Failure	23	PMID 32865004
EMPA-HEART	NCT02998970	P4	unknown	Diabetes	97	PMID 31434508
EmLiFa	NCT02637973	P4	completed	Type 2 Diabetes	84	—
EMPA-RenalTx	NCT03157414	P4	completed	Diabetes Mellitus	49	—
EMPHYT	NCT04203914	P4	completed	Hypertension	15	—
EMPATROPHY	NCT02728453	P4	terminated	Diabetes Mellitus Type 2	7	—
RECOVERY	NCT04381936	P3	recruiting	Pneumonia	70,000	PMID 38296965
PRECISE-CMD	NCT07533747	P3	not yet recruiting	Coronary Microvascular Dysfunction (CMD)	100	—
EMPASTONE	NCT06653738	P3	not yet recruiting	Kidney Stone	400	—
BI 690517	NCT07064473	P3	recruiting	Diabetes Mellitus, Type 2	11,800	—
BI 690517	NCT06935370	P3	recruiting	Heart Failure	4,200	—
EMPA-HEART-3	NCT06955260	P3	not yet recruiting	Congenital Heart Disease	410	—
EMPACT	NCT05271162	P3	active not recruiting	Cardiotoxicity	220	—
EMPA-AHF	NCT05392764	P3	recruiting	Acute Heart Failure	444	—
CANARY	NCT05715814	P3	recruiting	Peritoneal Dialysis Complication	20	—
PIEMONTE	NCT05028140	P3	recruiting	Type II Diabetes	480	—
EMPASHOCK	NCT05879276	P3	recruiting	Cardiogenic Shock	164	—
SEMPA	NCT06894784	P3	recruiting	Diabetes Type 1	36	PMID 30833170
TIME-SGLT2	NCT07065357	P3	enrolling by invitation	Metabolic Syndrome	160	—
EMPA-REPAIR	NCT05182658	P3	active not recruiting	Hypertrophic Cardiomyopathy	250	—
CONFIRMATION	NCT06024746	P3	recruiting	Heart Failure	1,500	—
EMPA-CON	NCT07038356	P3	recruiting	Acute Decompensated Heart Failure (ADHF)	536	—
CT-L03	NCT06571591	P3	completed	T2DM	606	—
DEMETER	NCT05905965	P3	recruiting	Metabolic Syndrome	200	—
EMPATHY	NCT05776043	P3	unknown	Acute Decompensated Heart Failure	1,364	—
PIONEER START	NCT05444153	P3	withdrawn	Diabetes Mellitus, Type 2	0	—
EGITO	NCT04970108	P3	withdrawn	Hypertension Associated	0	—
ADDEMFEP	NCT06683053	P3	active not recruiting	Congestive Heart Failure (CHF)	90	—
EMPA post-GDM	NCT03215069	P3	completed	Gestational Diabetes	91	PMID 40964955
EMPOAF	NCT06124937	P3	unknown	Post-operative Atrial Fibrillation	492	—
EmpHy	NCT05036317	P3	terminated	Postprandial Hypoglycemia	40	—
EMPRESS-MI	NCT05020704	P3	unknown	Myocardial Infarction	100	—
PROVE	NCT04345796	P3	completed	Tricuspid Regurgitation	56	—
EMPA	NCT05556044	P3	unknown	Acute Heart Failure	200	—
The CANA -AHF	NCT05364190	P3	completed	Chronic Heart Failure	142	—
EMPACT-MI	NCT04509674	P3	completed	Myocardial Infarction	6,522	PMID 38588929
DINAMO	NCT03429543	P3	completed	Diabetes Mellitus, Type 2	175	PMID 36738751
EMPIRE-02	NCT04221152	P3	unknown	Insulin Resistance - Type A	8	—
UGT	NCT05036421	P3	completed	Pharmacogenomic	18	—
EMMY	NCT03087773	P3	completed	Acute Myocardial Infarction	476	PMID 36036746
EMPIRE-01	NCT04018365	P3	unknown	Insulin Resistance - Type A	8	PMID 38216831
CLASS17	NCT03979352	P3	completed	Type1 Diabetes Mellitus	28	—
4T	NCT04131582	P3	unknown	Prediabetic State	34	PMID 20489418
(MEDiaN)	NCT03933956	P3	terminated	Diabetic Nephropathies	2	PMID 24026259
SIMPLE	NCT03151343	P3	completed	Type2 Diabetes Mellitus	92	PMID 35061894
EMPACEF	NCT03118336	P3	completed	Type 2 Diabetes	56	PMID 37424866
ELMI	NCT02752113	P3	completed	Diabetes Mellitus Type 2	101	PMID 37268640
SOTA-EMPA	NCT03351478	P3	completed	Type 2 Diabetes Mellitus	770	—
PIONEER 2	NCT02863328	P3	completed	Diabetes	822	PMID 31530666
EASE-2	NCT02414958	P3	completed	Diabetes Mellitus, Type 1	730	PMID 37616393
EASE-3	NCT02580591	P3	completed	Diabetes Mellitus, Type 1	977	PMID 30287422
BI 10773	NCT02182830	P3	completed	Diabetes Mellitus, Type 2	166	PMID 29139301
PPG	NCT01947855	P3	completed	Diabetes Mellitus, Type 2	60	PMID 31444706
EMPA-CKD	NCT07175051	P2	recruiting	Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)	20	PMID 30945006
EmPATH	NCT06992440	P2	enrolling by invitation	Pulmonary Arterial Hypertension	78	—
EMPA	NCT06745063	P2	recruiting	Obesity	50	—
EMPA-CKD	NCT07060417	P2	not yet recruiting	Non-diabetic Chronic Kidney Disease	52	—
COMPARE-VS	NCT07304817	P2	recruiting	CKD	100	—
SLIDE	NCT03867487	P2	not yet recruiting	Non-Alcoholic Fatty Liver Disease	40	—
SHIELD	NCT06355310	P2	recruiting	Non-Alcoholic Fatty Liver Disease	40	—
ESS-AKD	NCT06528405	P2	recruiting	Acute Kidney Injury	264	—
PEP-DM	NCT06729996	P2	recruiting	Pancreatitis, Chronic	40	—
SAK	NCT05138575	P2	recruiting	Heart Failure With Preserved Ejection Fraction	53	—
REDMeD	NCT06643442	P2	not yet recruiting	DMD-associated Dilated Cardiomyopathy	12	PMID 21245364
CRAVE	NCT06570473	P2	recruiting	Pulmonary Hypertension	30	—
SEED	NCT05786443	P2	recruiting	End Stage Renal Disease	60	—
EMPIRIC-PD	NCT06483074	P2	recruiting	End Stage Renal Disease on Dialysis	48	—
EMPA-PCI	NCT06342141	P2	active not recruiting	STEMI	162	PMID 35705980
EMPA Liver	NCT05726032	P2	recruiting	Cirrhosis	20	—
SGLT2	NCT05757791	P2	recruiting	Major Depressive Disorder	16	—
HER2HEART-US	NCT06844669	P2	terminated	HER2-positive Breast Cancer	7	—
Hypo-PrEA	NCT05174507	P2	withdrawn	Postprandial Hypoglycemia	0	—
CREST-KT	NCT04906213	P2	terminated	Kidney Transplant; Complications	20	PMID 26981940
SIDIA	NCT06435858	P2	recruiting	Autosomal Dominant Polycystic Kidney Disease	40	PMID 39356039
EmFin-Nx	NCT06818305	P2	terminated	Renal Cell Carcinoma (Kidney Cancer)	10	—
EMPA-DMMI	NCT07169981	P2	completed	Diabete Mellitus	200	—
EMPAtia	NCT04930627	P2	unknown	Glucose 6 Phosphatase Deficiency	20	—
CONFIDENCE	NCT05254002	P2	completed	Type 2 Diabetes Mellitus	1,664	PMID 39037799
Emphower PoC	NCT05493371	P2	completed	Idiopathic Pulmonary Arterial Hypertension	8	—
NASH	NCT05282121	P2	terminated	Liver Diseases	90	PMID 37095557
LEGEND	NCT05232071	P2	completed	NASH - Nonalcoholic Steatohepatitis	42	—
DIASA3	NCT04662866	P2	unknown	Impaired Glucose Tolerance	64	—
NATRIURETIC	NCT04535960	P2	unknown	Type 2 Diabetes Mellitus	36	—
SWEETSTONE	NCT04911660	P2	completed	Kidney Stone	50	PMID 35288397
EMPATHY	NCT04143581	P2	withdrawn	Obesity	0	—
EMPAG-HF	NCT04049045	P2	completed	Acute Decompensated Heart Failure	60	PMID 35766022
GLYCO-1B	NCT04138251	P2	unknown	Glycogen Storage Disease Type I	5	—
ELSI	NCT03128528	P2	completed	Chronic Heart Failure	84	PMID 34753480
ESRD	NCT03713190	P2	completed	End Stage Renal Disease	25	—
EMPOX	NCT02890745	P2	completed	Diabetes Mellitus, Type 2	31	PMID 28490557
Empire HF	NCT03198585	P2	completed	Heart Failure With Reduced Ejection Fraction	190	PMID 35219331
EMPA-RESPONSE	NCT03200860	P2	completed	Heart Failure Acute	80	—
EMPRA	NCT03078101	P2	completed	Diabetic Kidney Disease	51	—
EMPA	NCT03132181	P2	completed	Diabetes Mellitus Type 2 (T2DM)	40	PMID 24939043
EMPA-REIN	NCT03093103	P2	completed	Nephropathy	45	PMID 35391843
EMPTRA-DM	NCT03113110	P2	completed	Posttransplant Diabetes Mellitus	16	PMID 30585690
BI 10773	NCT01649297	P2	completed	Diabetes Mellitus, Type 2	983	—

Terminated and withdrawn Empagliflozin trials (29)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05885074withdrawnMechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors
NCT06083675withdrawnResearch Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
NCT06844669terminatedHER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
NCT05174507withdrawnEmpagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
NCT04906213terminatedCardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
NCT05058417withdrawnAssessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis
NCT06818305terminatedEfficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT
NCT05444153withdrawnResearch Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
NCT04970108withdrawnEfficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
NCT05960617withdrawnEfficacy and Safety of Empagliflozin in GSD-Ib Patients
NCT05036317terminatedEmpagliflozin for the Treatment of Postprandial Hypoglycemia
NCT05282121terminatedA Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
NCT05129722terminatedPolydiuretic Therapy for HFpEF, a Randomised Controlled Trial
NCT03437330withdrawnEmpagliflozin Effect on Glucose Toxicity
NCT04917692withdrawnEmpagliflozin in Adolescent Diabetes
NCT05102071withdrawnClinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
NCT04243850withdrawnREGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations
NCT04143581withdrawnSGLT2 Inhibitors in Glomerular Hyperfiltration
NCT03554200terminatedEMPA Acute Heart Failure
NCT03933956terminatedMetabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
NCT03173963withdrawnEmpaglifozin in Early Diabetic Kidney Disease
NCT03504566withdrawnRotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
NCT03642184terminatedEfficacy and Safety of Empagliflozin in NODAT
NCT02768220withdrawnThe Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
NCT02985242terminatedEmpagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
NCT03152552terminatedA Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
NCT03060980terminatedComparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
NCT02728453terminatedSGLT2 Inhibition and Left Ventricular Mass
NCT01984606withdrawnEfficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

All Empagliflozin trials (428)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT04381936	RECOVERY	Randomised Evaluation of COVID-19 Therapy	P3	recruiting	70,000	University of Oxford	Mar 2020
NCT05501483	DiaSpax	Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes	N/A	recruiting	60	Karolinska Institutet	Feb 2023
NCT07533747	PRECISE-CMD	PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction	P3	not yet recruiting	100	King's College London	May 2026
NCT06249932	EMPA-RRED	Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease	P4	recruiting	95	National Taiwan University Hospital	Mar 2024
NCT06249945	EMPA-PRED	EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease	P4	recruiting	150	National Taiwan University Hospital	Mar 2024
NCT06642623	ENVELOP	A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients	P4	recruiting	2,862	Yonsei University	Jan 2024
NCT07175051	EMPA-CKD	Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin	P2	recruiting	20	University of Illinois at Chicago	Apr 2026
NCT06992440	EmPATH	Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension	P2	enrolling by invitation	78	Gustavo A Heresi, MD, MS	Jun 2025
NCT06653738	EMPASTONE	Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention	P3	not yet recruiting	400	Insel Gruppe AG, University Hospital Bern	Jun 2026
NCT03424005	Morpheus-panBC	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	recruiting	1,132	Hoffmann-La Roche	Mar 2018
NCT06013865	SEKTR	Empagliflozin Treatment in Kidney Transplant Recipients	P4	recruiting	264	VA Office of Research and Development	Apr 2024
NCT06625073		Randomized Trial of SGLT2i in Heart Transplant Recipients	P4	recruiting	200	VA Office of Research and Development	Jan 2026
NCT06745063	EMPA	Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity	P2	recruiting	50	VA Office of Research and Development	May 2025
NCT07064473	BI 690517	EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	P3	recruiting	11,800	Boehringer Ingelheim	Jul 2025
NCT07060417	EMPA-CKD	Vascular Effects of SGLT2i in Non-diabetic CKD	P2	not yet recruiting	52	VA Office of Research and Development	Aug 2026
NCT07322237	DICE	DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis	P4	recruiting	400	Post Graduate Institute of Medical Education and Research, Chandigarh	Apr 2026
NCT07107945		A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)	P3	recruiting	120	Boehringer Ingelheim	Dec 2025
NCT06715449	EMPA-ESUS	EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source	P2/P3	recruiting	100	University of East Anglia	Nov 2024
NCT06506422	ERASE-Aging	Empagliflozin Reversal of Arterial StiffnEss in Aging	P2/P3	recruiting	80	University of Missouri-Columbia	Aug 2024
NCT06935370	BI 690517	A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart	P3	recruiting	4,200	Boehringer Ingelheim	May 2025
NCT06507657		Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure	Early P1	recruiting	80	University of Minnesota	Dec 2024
NCT06642272	APPLE TREE	A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record	P4	recruiting	17,200	Herlev and Gentofte Hospital	Oct 2024
NCT07228195	SIT	SGLT2i Therapy in Islet Transplantation (SIT)	P4	not yet recruiting	40	University of Minnesota	Jul 2026
NCT06110130	EMPA CKD	Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD	P4	recruiting	60	Washington D.C. Veterans Affairs Medical Center	Feb 2024
NCT06762314		Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes	P2	recruiting	105	Mostafa Bahaa	Jan 2025
NCT06531824		EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)	P3	recruiting	11,000	Boehringer Ingelheim	Aug 2024
NCT06424288		A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure	P3	recruiting	6,000	Boehringer Ingelheim	Jun 2024
NCT07348484		Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors	—	not yet recruiting	300	Instituto de Investigación Biomédica de Salamanca	Jan 2026
NCT06955260	EMPA-HEART-3	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure	P3	not yet recruiting	410	Subodh Verma	May 2025
NCT07304817	COMPARE-VS	Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)	P2	recruiting	100	University Medical Center Groningen	May 2026
NCT06674109	SAVE-Care	SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial	P4	recruiting	60	Massachusetts General Hospital	May 2026
NCT05271162	EMPACT	Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines	P3	active not recruiting	220	Maria Sklodowska-Curie National Research Institute of Oncology	Sep 2023
NCT03867487	SLIDE	SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease	P2	not yet recruiting	40	Justin Ryder	May 2027
NCT06355310	SHIELD	Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease	P2	recruiting	40	Justin Ryder	Apr 2025
NCT07074418	EMPA[10-20]	Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2	P4	not yet recruiting	34	Centre Hospitalier Universitaire de Nice	Apr 2026
NCT07055282		SGLT2i in Kidney Stones	Early P1	recruiting	32	University of Chicago	Nov 2025
NCT06528405	ESS-AKD	The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease	P2	recruiting	264	National Taiwan University Hospital	Nov 2024
NCT06613854	E-SEMPA	Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes	P4	recruiting	90	University Medical Centre Ljubljana	Oct 2024
NCT06519448	RedNASH	Reducing Non-Alcoholic Steatohepatitis	N/A	enrolling by invitation	30	Military University Hospital, Prague	Apr 2024
NCT05392764	EMPA-AHF	Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure	P3	recruiting	444	Juntendo University	Sep 2022
NCT05147090		Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients	P4	active not recruiting	106	The University of Hong Kong	Jan 2022
NCT07336797		Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy	P2	recruiting	66	Abdelrahman Mahmoud	Sep 2025
NCT05715814	CANARY	meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis	P3	recruiting	20	University Health Network, Toronto	Sep 2024
NCT07292909	EMPANTINFLAM	Effect of Empagliflozin on Inflammation	P4	recruiting	100	Hotel Dieu de France Hospital	Sep 2025
NCT05028140	PIEMONTE	Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus	P3	recruiting	480	EMS	Oct 2024
NCT04602754		Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.	P3	recruiting	228	EMS	Dec 2023
NCT07146880		Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome	P2	not yet recruiting	10	National Taiwan University Hospital	Sep 2025
NCT07365358	EMPAGO	Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients	P4	not yet recruiting	200	Chong Kun Dang Pharmaceutical	Mar 2026
NCT07155694		Role of Finerenone in African American Veterans With Diabetic Kidney Disease	P4	not yet recruiting	30	Washington D.C. Veterans Affairs Medical Center	Sep 2025
NCT05164263	EASE	Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study	P4	recruiting	2,000	Getz Pharma	Apr 2021
NCT06668753		Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	—	not yet recruiting	114	Assiut University	Nov 2024
NCT07053319		SGLT2i, Pioglitazone, and Ketone Production in T2D	P1	recruiting	64	The University of Texas Health Science Center at San Antonio	May 2026
NCT07053306		SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia	P1	recruiting	29	The University of Texas Health Science Center at San Antonio	Apr 2025
NCT05885074		Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors	P2	withdrawn	0	University of Alabama at Birmingham	Jan 2025
NCT07053293		SGLT2i, Hepatic Glucose Production, and SNS	Early P1	recruiting	22	The University of Texas Health Science Center at San Antonio	Jan 2025
NCT06989723		Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes	P4	recruiting	120	Seoul National University Bundang Hospital	Jan 2025
NCT04670666		Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus	P3	recruiting	270	EMS	Nov 2024
NCT05960656		SGLTi, Hepatic Glucose Production and Ketogenesis	P1	recruiting	30	The University of Texas Health Science Center at San Antonio	Oct 2023
NCT06260059	EmpaCHD	Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease	P4	recruiting	40	Anita Saraf	Sep 2024
NCT06729996	PEP-DM	Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus	P2	recruiting	40	Mayo Clinic	May 2025
NCT06391450	EMPA-PKD	Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)	P4	active not recruiting	44	Hannover Medical School	Jun 2024
NCT05138575	SAK	SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial	P2	recruiting	53	University of Pennsylvania	Jan 2022
NCT06083675		Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes	P3	withdrawn	0	Novo Nordisk A/S	Jan 2024
NCT07093476		Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin	P3	recruiting	171	Celltrion	Jul 2025
NCT07442006		Glycemic Variability of Combination Therapies in T2DM	P4	recruiting	178	JW Pharmaceutical	Oct 2025
NCT06643442	REDMeD	Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age	P2	not yet recruiting	12	Sebastiano Lava	Oct 2025
NCT05057806		SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan	Early P1	recruiting	30	The University of Texas Health Science Center at San Antonio	Jan 2021
NCT05879276	EMPASHOCK	Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.	P3	recruiting	164	Central Hospital, Nancy, France	Dec 2024
NCT06229678		Ketones, SGLT2, HFrEF	Early P1	recruiting	71	The University of Texas Health Science Center at San Antonio	Jan 2024
NCT06473844		Efficacy of SGLT2 Inhibitors in Adults With Sepsis	N/A	recruiting	60	Hospital Authority, Hong Kong	Mar 2025
NCT04447911	EMPOWER	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia	P4	recruiting	172	University Hospital, Basel, Switzerland	Feb 2021
NCT07372040		Add-on Diuretics in Acute Decompensated Heart Failure	P2	recruiting	66	Tanta University	Feb 2026
NCT06894784	SEMPA	A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes	P3	recruiting	36	McGill University Health Centre/Research Institute of the McGill University Health Centre	Apr 2025
NCT07472920	EMPA-BD	Empagliflozin Adjunctive Therapy in Bipolar Depression	N/A	not yet recruiting	20	University of Sao Paulo	Mar 2026
NCT07311551	BMI	A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)	P4	not yet recruiting	112	Bhavya Bhavya, MD	Dec 2025
NCT07065357	TIME-SGLT2	Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor	P3	enrolling by invitation	160	The University of Hong Kong	Aug 2025
NCT06570473	CRAVE	Feasibility Trial for a Right Ventricular Failure Platform Trial	P2	recruiting	30	University of Alberta	Jul 2025
NCT06030843	TREAT-CRS	The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1	P2/P3	recruiting	200	Chulalongkorn University	Mar 2025
NCT06554301		A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension	P1	recruiting	72	China National Center for Cardiovascular Diseases	Oct 2024
NCT06055452		Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension	P4	recruiting	120	China National Center for Cardiovascular Diseases	Jan 2024
NCT06149793		SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes	P2/P3	active not recruiting	8	University of Minnesota	Jan 2024
NCT05669742		Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients	P3	recruiting	40	Tanta University	May 2023
NCT05671991	EMPA-PD	Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease	P4	recruiting	30	Yale University	Mar 2023
NCT05426525		Use of Empagliflozin to Treat Prediabetes	P4	active not recruiting	60	Oregon State University	Oct 2022
NCT05786443	SEED	Safety and Efficacy of Empagliflozin in Hemodialysis	P2	recruiting	60	NYU Langone Health	Jan 2024
NCT05972564	SADIE2	The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function	P1/P2	recruiting	74	Vanderbilt University Medical Center	Sep 2023
NCT06706791		Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II	P4	recruiting	156	Fazaia Ruth Pfau Medical College	Apr 2025
NCT05610956		Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis	Early P1	recruiting	60	Tanta University	Jan 2023
NCT05182658	EMPA-REPAIR	Empagliflozin in Hypertrophic Cardiomyopathy	P3	active not recruiting	250	National Institute of Cardiology, Warsaw, Poland	Jun 2022
NCT07303556	ICDDTKZ26	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs	N/A	active not recruiting	120	Nazarbayev University	Dec 2024
NCT06483074	EMPIRIC-PD	Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients	P2	recruiting	48	Chinese University of Hong Kong	Jul 2024
NCT07214818	SGLT2-NS	SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome	P2/P3	recruiting	75	Mansoura University	Nov 2025
NCT06024746	CONFIRMATION	A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)	P3	recruiting	1,500	Colorado Prevention Center	Jul 2024
NCT07198191	SGLT2i-AMI	SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study	—	active not recruiting	200,000	Yonsei University	Sep 2014
NCT06926660		A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease	P2	active not recruiting	492	Boehringer Ingelheim	Jul 2025
NCT05510115		Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease	P2	active not recruiting	50	University of Colorado, Denver	Nov 2022
NCT06410352		Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome	P4	recruiting	220	University Medical Center, Kazakhstan	Mar 2024
NCT05313529	LIGHT-MCI	LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes	N/A	active not recruiting	396	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Oct 2022
NCT06430684	SGLT2I-IN-KIDS	Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease	Early P1	recruiting	40	Ann & Robert H Lurie Children's Hospital of Chicago	Aug 2024
NCT05360615		The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors	P1	active not recruiting	147	Chulalongkorn University	Jul 2022
NCT07452913		Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes	P4	enrolling by invitation	110	Bahria University	Jan 2026
NCT07038356	EMPA-CON	Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure	P3	recruiting	536	Christian Schulze	Dec 2025
NCT06862739	GLYCO-3P	Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination	P4	recruiting	800	Nabiqasim Industries (Pvt) Ltd	Oct 2025
NCT06851962	EPHIC-DIA2	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.	P4	active not recruiting	504	Fundación para la Investigación del Hospital Clínico de Valencia	May 2025
NCT03363464		Comparative Effectiveness of Empagliflozin in the US	—	active not recruiting	230,000	Boehringer Ingelheim	Oct 2017
NCT05687058		Empagliflozin in ESKD - A Feasibility Study	P1/P2	active not recruiting	24	University of Mississippi Medical Center	Nov 2023
NCT06342141	EMPA-PCI	Empagliflozin for No-reflow Phenomenon in PCI for STEMI	P2	active not recruiting	162	Instituto Nacional de Cardiologia Ignacio Chavez	Aug 2024
NCT07331389		A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin	P1	recruiting	111	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Sep 2025
NCT05726032	EMPA Liver	Empagliflozin in Patients With Cirrhosis and Ascites	P2	recruiting	20	Yale University	Sep 2023
NCT05757791	SGLT2	Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)	P2	recruiting	16	NYU Langone Health	Mar 2023
NCT06171802	EMPAVR	EMPagliflozin After Aortic Valve Replacement	P4	completed	206	Rigshospitalet, Denmark	Feb 2024
NCT06844669	HER2HEART-US	HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy	P2	terminated	7	Washington University School of Medicine	Apr 2025
NCT06571591	CT-L03	Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin	P3	completed	606	Celltrion	Aug 2024
NCT05174507	Hypo-PrEA	Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes	P2	withdrawn	0	University Hospital, Basel, Switzerland	Jun 2022
NCT05905965	DEMETER	Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment	P3	recruiting	200	Collegium Medicum w Bydgoszczy	May 2023
NCT07120828	CYP8B1-SGLT2-T	The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	P4	completed	260	Erbil Polytechnic University	Jul 2025
NCT05305495	DRIP-AHF-1	Empagliflozin in Acute Heart Failure	P4	completed	25	McGill University Health Centre/Research Institute of the McGill University Health Centre	Dec 2022
NCT07379788		ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling	N/A	completed	180	Rehab Werida	Jan 2025
NCT07180745		Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease	P4	not yet recruiting	400	Badr University	Nov 2025
NCT06469645		The Role of SGLT2i in Management of Moderate AS	P2/P3	unknown	104	University of East Anglia	May 2024
NCT06618976	SOTATHROMBUS	Antithrombotic Activities of Sotagliflozin vs. Empagliflozin	P4	completed	17	Icahn School of Medicine at Mount Sinai	Feb 2025
NCT04906213	CREST-KT	CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients	P2	terminated	20	Duke University	Jul 2022
NCT07372118		Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition	P1	completed	32	Humanis Saglık Anonim Sirketi	Sep 2025
NCT06187493		Treatment of Patients With Diabetic Kidney Disease	N/A	unknown	70	Assiut University	Jan 2024
NCT06846411	EMPA-FIT	The EMPA-FIT Study	P4	recruiting	46	Seoul National University Bundang Hospital	Jan 2024
NCT05140694		Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D	P4	unknown	135	Seoul National University Bundang Hospital	Dec 2023
NCT07003191		Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes	—	active not recruiting	2,600	Sun Yat-sen University	Aug 2023
NCT05776043	EMPATHY	Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure	P3	unknown	1,364	Medical University of Warsaw	Mar 2022
NCT05058417		Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis	P2	withdrawn	0	Sadat City University	Oct 2021
NCT04639414	COMBAT_T2_NASH	Combined Active Treatment in Type 2 Diabetes with NASH	P4	active not recruiting	192	German Diabetes Center	Mar 2021
NCT05638880		Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease	P2	completed	60	Mostafa Bahaa	Dec 2022
NCT06098625	EmLina Renal	Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus	N/A	unknown	200	Medanta, The Medicity, India	Nov 2023
NCT06095492	EmLinaRenal	Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus	N/A	recruiting	200	Medanta, The Medicity, India	Oct 2023
NCT06284850		Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels	—	unknown	40	Aristotle University Of Thessaloniki	Nov 2023
NCT05553938	EMPA HF	Effects of Acute and Chronic Empagliflozin Heart Failure	P1	recruiting	60	Yale University	Aug 2023
NCT07531108		Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes	P4	completed	186	Hawler Medical University	Nov 2024
NCT07541456	EMPA-BP	Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes	P4	completed	300	Dr. Zarmina Younes	Jun 2025
NCT06435858	SIDIA	Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease	P2	recruiting	40	Cantonal Hospital Graubuenden	Sep 2024
NCT05584319	EMPAGUM	EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction	P4	unknown	100	Zhijun Sun	Dec 2022
NCT05600387		Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	P4	unknown	100	Zhijun Sun	Nov 2022
NCT07133399		A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood	P1	completed	32	Boehringer Ingelheim	Sep 2025
NCT07102719		Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers	P1	completed	40	Handok Inc.	Sep 2025
NCT07266766		Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg	P1	completed	40	Humanis Saglık Anonim Sirketi	Aug 2025
NCT06818305	EmFin-Nx	Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT	P2	terminated	10	Jinling Hospital, China	Jan 2025
NCT06094920	Optimize@Home	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial	P4	completed	12	University Medical Center Groningen	Jul 2024
NCT07213895		Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets	P1	completed	14	Humanis Saglık Anonim Sirketi	May 2025
NCT06962826		A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food	P1	completed	14	Boehringer Ingelheim	May 2025
NCT06828731	PREVNT	Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes	P1	completed	60	Charles George VA Medical Center	Dec 2024
NCT06012266		Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale	P2	unknown	12	Centre Hospitalier Universitaire Vaudois	Aug 2024
NCT04603508		Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia	P3	unknown	240	EMS	Mar 2023
NCT05444153	PIONEER START	Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity	P3	withdrawn	0	Novo Nordisk A/S	Oct 2022
NCT04918407		Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation	N/A	completed	40	Shahid Beheshti University of Medical Sciences	Jan 2022
NCT06401343		Use of SGLT2i in noHCM With HFpEF	P4	unknown	94	China National Center for Cardiovascular Diseases	Aug 2022
NCT07112274		Empagliflozin on Patients With Preserved Heart Failure	N/A	completed	50	Damanhour University	Oct 2022
NCT06759922		Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes	P4	completed	172	Bahria University	Jan 2025
NCT05614115		Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD	P1	completed	62	University of Utah	Mar 2023
NCT07169981	EMPA-DMMI	Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF	P2	completed	200	Ain Shams University	Jul 2023
NCT07039890		To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.	P1	completed	40	Humanis Saglık Anonim Sirketi	Mar 2025
NCT05967156		Empagliflozin in Heart Failure Dialysis Patients	N/A	completed	30	Shahid Beheshti University of Medical Sciences	Jun 2023
NCT06187285		Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia	N/A	completed	220	Medanta, The Medicity, India	Jan 2024
NCT06021145	AID	Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes	P4	recruiting	46	McGill University Health Centre/Research Institute of the McGill University Health Centre	Apr 2024
NCT04970108	EGITO	Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension	P3	withdrawn	0	EMS	Aug 2023
NCT06823856		Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)	P1	completed	64	Gedeon Richter Plc.	May 2025
NCT05078879		Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency	P1	completed	4	National Institute of Allergy and Infectious Diseases (NIAID)	Nov 2021
NCT07556094	HF(L)OSA	Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.	N/A	completed	70	Medical University of Bialystok	Jun 2023
NCT06889350		Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers	P1	completed	40	Handok Inc.	Mar 2025
NCT06641128		The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate	P4	not yet recruiting	44	Tanta University	Oct 2024
NCT06792968		Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)	P1	completed	64	Gedeon Richter Plc.	Mar 2025
NCT06932159		Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets	P1	completed	40	Humanis Saglık Anonim Sirketi	Dec 2024
NCT07367555	SGLT-2	Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients	P1	completed	360	Ariba Shafiq	Oct 2024
NCT04930627	EMPAtia	Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia	P2	unknown	20	Children's Memorial Health Institute, Poland	Jul 2021
NCT05254002	CONFIDENCE	A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes	P2	completed	1,664	Bayer	Jun 2022
NCT05073692	ON TARGET DM	Comparison of Type 2 Diabetes Pharmacotherapy Regimens	—	completed	241,981	Kaiser Permanente	Jul 2021
NCT06766500		Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)	P1	completed	64	Gedeon Richter Plc.	Jan 2025
NCT06683053	ADDEMFEP	Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department	P3	active not recruiting	90	Conrado Roberto Hoffmann Filho	Mar 2023
NCT04541797	CATCH-EM	Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)	N/A	active not recruiting	160	The University of Hong Kong	Oct 2020
NCT05042973		The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure	P2	completed	165	Jacob Moller	Sep 2021
NCT05084235		The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure	P2	completed	191	Jacob Moller	Sep 2021
NCT06915870		Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment	N/A	completed	108	Fatima Maqsood	Jul 2024
NCT06952231		Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus	P3	completed	50	University of Lahore	May 2024
NCT05960617		Efficacy and Safety of Empagliflozin in GSD-Ib Patients	P2	withdrawn	0	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Jul 2023
NCT03215069	EMPA post-GDM	Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes	P3	completed	91	Mount Sinai Hospital, Canada	Jul 2018
NCT06124937	EMPOAF	Empagliflozin to Prevent Post-Operative Atrial Fibrillation	P3	unknown	492	Rajaie Cardiovascular Medical and Research Center	Nov 2023
NCT06065280		Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients	N/A	completed	80	Damanhour University	Nov 2022
NCT03912909	EMPA-SNS	Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans	P4	unknown	30	Royal Perth Hospital	Aug 2018
NCT05778084		Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction	P4	unknown	60	Alexandria University	Dec 2022
NCT07479108	EB-24-003	Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions	N/A	completed	32	ADIUM	Nov 2024
NCT06578676		To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults	P1	recruiting	56	Hyundai Pharm	Jun 2024
NCT05605158		Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis	P3	unknown	56	Tanta University	Nov 2022
NCT06350903	SWEET-HEART	Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging	N/A	completed	16	Matthieu Pelletier-Galarneau, MD MSc	Jun 2024
NCT05493371	Emphower PoC	Empagliflozin in Pulmonary Arterial Hypertension	P2	completed	8	Amsterdam UMC, location VUmc	Mar 2023
NCT06313008		Empagliflozin Versus Vildagliptin in CAD Patients With T2DM	N/A	completed	120	Damanhour University	Aug 2023
NCT05911724		Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.	—	completed	180	Damanhour University	Mar 2023
NCT05081219		SNIFF - Combo INI+EMPA Trial	P2	completed	47	Wake Forest University Health Sciences	Sep 2021
NCT06201000		Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients	—	unknown	282	October 6 University	Dec 2023
NCT06103279		Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin	P2/P3	unknown	40	Ain Shams University	Nov 2023
NCT05036317	EmpHy	Empagliflozin for the Treatment of Postprandial Hypoglycemia	P3	terminated	40	University Hospital, Basel, Switzerland	Mar 2022
NCT04853615		SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?	—	unknown	800	Fayoum University	Jul 2021
NCT05350202		Emp-Activity: Empagliflozin Functional Capacity	—	completed	3,431	Boehringer Ingelheim	Dec 2022
NCT06337409		Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers	P1	unknown	30	International Bio service	Jul 2024
NCT05130463	PMS	Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus	—	completed	1,053	Boehringer Ingelheim	Mar 2022
NCT03594110		EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)	P3	completed	6,609	Boehringer Ingelheim	Jan 2019
NCT06140108		Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity	P2/P3	completed	70	SINA Health Education and Welfare Trust	Dec 2023
NCT06339788		Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers	P1	completed	40	Handok Inc.	May 2024
NCT05020704	EMPRESS-MI	EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction	P3	unknown	100	NHS Greater Glasgow and Clyde	Sep 2022
NCT06308679		A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions	P1	unknown	28	Pharma Nueva	May 2024
NCT05282121	NASH	A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)	P2	terminated	90	Boehringer Ingelheim	Jun 2022
NCT05232071	LEGEND	Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus	P2	completed	42	Inventiva Pharma	Jun 2022
NCT04345796	PROVE	Pharmacological Reduction of Right Ventricular Enlargement	P3	completed	56	Asan Medical Center	Feb 2021
NCT05545800		Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy	P3	unknown	78	Xiangya Hospital of Central South University	Sep 2022
NCT05373004	SGLT2i VS ACEi	Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease	P2/P3	unknown	212	Omar Tarek Elfarargi	Mar 2023
NCT05556044	EMPA	Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction	P3	unknown	200	Chinese University of Hong Kong	Sep 2022
NCT05129722		Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial	P4	terminated	3	The George Institute	Oct 2022
NCT05942963		Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD	P4	unknown	240	Jinnah Postgraduate Medical Centre	Oct 2023
NCT04583813	EMPA-AF	Empagliflozin and Atrial Fibrillation Treatment	P4	unknown	400	Miulli General Hospital	Sep 2021
NCT06232239		Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg	P1	unknown	26	Bio-innova Co., Ltd	Feb 2024
NCT05694923	Fatty liver	Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment	N/A	completed	55	Assiut University	Apr 2023
NCT05373680		Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression	P2/P3	completed	118	Tanta University	Jan 2022
NCT04117763	EMPATHYHEART	Effect of Empagliflozin on Ventricular Repolarization.	P4	completed	90	University of Sao Paulo	Oct 2019
NCT05580510		" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "	P2/P3	unknown	160	Instituto Nacional de Cardiologia Ignacio Chavez	Feb 2023
NCT03464045		Empa PASS on Urinary Tract Malignancies	—	completed	344,995	Boehringer Ingelheim	Nov 2016
NCT06145360	OAD	Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient	P4	completed	150	SINA Health Education and Welfare Trust	Dec 2023
NCT05364190	The CANA -AHF	Canagliflozin in Patients With Acute Decompansted Heart Failure	P3	completed	142	October 6 University	Jun 2022
NCT05139472		Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction	P4	completed	8	University of Texas Southwestern Medical Center	Nov 2021
NCT04523064	POST-CABGDM	POST-CABGDM: Empagliflozin in Perioperative CABG	P4	completed	155	University of Sao Paulo General Hospital	Sep 2020
NCT03193684		Empagliflozin and Hepatic Glucose Metabolism	P4	completed	72	The University of Texas Health Science Center at San Antonio	May 2018
NCT05347459		Cognitive Protective Effect of Newer Antidiabetic Drugs	—	unknown	100	Alexandria University	Mar 2022
NCT04986735		Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin	—	unknown	11	Hong Kong Children's Hospital	Aug 2021
NCT04796428	GOLDEN-AGE	GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial	P4	unknown	1,167	Center for Outcomes Research and Clinical Epidemiology, Italy	Jun 2021
NCT03877406		Effect of Empagliflozin on Body Composition and Ketones	P4	unknown	200	Seoul National University Bundang Hospital	Aug 2018
NCT04907214		SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot	P1/P2	completed	29	Vanderbilt University Medical Center	Jul 2021
NCT06204107		A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379	P1	completed	28	Chong Kun Dang Pharmaceutical	Nov 2023
NCT04203927	EJB051	Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes	Early P1	unknown	50	University of Virginia	Feb 2020
NCT04976283		Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver	P4	unknown	123	Getz Pharma	Sep 2021
NCT04509674	EMPACT-MI	EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)	P3	completed	6,522	Boehringer Ingelheim	Dec 2020
NCT04662866	DIASA3	Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose	P2	unknown	64	Oslo University Hospital	Feb 2021
NCT04535960	NATRIURETIC	Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial	P2	unknown	36	University Health Network, Toronto	Jan 2019
NCT06180109		Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition	P1	completed	36	Humanis Saglık Anonim Sirketi	Jul 2023
NCT05977465		Empagliflozin in Treatment of Peripheral Diabetic Neuropathy	P1/P2	completed	50	Tanta University	Jan 2022
NCT05182840		A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease	P2	completed	714	Boehringer Ingelheim	Jan 2022
NCT05512130		Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy	Early P1	unknown	18	Washington University School of Medicine	Aug 2022
NCT05013502	DRAin-Em 01	Empagliflozin in Diuretic Refractory Ascites	P1	completed	14	Stanford University	Nov 2021
NCT04642261		Effect of Empagliflozin on Liver Fat in Non-diabetic Patients	P4	completed	98	The University of Hong Kong	Jan 2021
NCT05417646	MOD3ST-CLAMP	Impact of SGLT2 on Glucosuria in HNF1A-MODY	N/A	completed	21	Steno Diabetes Center Copenhagen	Jun 2022
NCT03429543	DINAMO	Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM	P3	completed	175	Boehringer Ingelheim	Mar 2018
NCT06825156	MERCURI	Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors	P4	completed	60	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Mar 2022
NCT03437330		Empagliflozin Effect on Glucose Toxicity	P4	withdrawn	0	University Hospital Tuebingen	Oct 2021
NCT05465317		Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease	—	completed	62,197	Boehringer Ingelheim	Aug 2022
NCT07247656		The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .	P4	completed	200	Bahria University	Dec 2022
NCT05233163		SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy	P4	completed	15	Columbia University	Mar 2022
NCT04911660	SWEETSTONE	Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers	P2	completed	50	Insel Gruppe AG, University Hospital Bern	Aug 2021
NCT05857085	ENDIS	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	P4	completed	90	General and Teaching Hospital Celje	Dec 2021
NCT05681273		Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.	P1	completed	48	Chipscreen Biosciences, Ltd.	Feb 2023
NCT05822674		Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio	—	completed	80	University of Diyala	Jan 2022
NCT05956522		Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects	P1	completed	106	The Affiliated Hospital of Qingdao University	Jul 2022
NCT05037695	SAFE-PCI	SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)	P4	unknown	40	University of Sao Paulo General Hospital	Jul 2021
NCT05103306	LUCID	Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy	—	unknown	300	Chungbuk National University Hospital	Jan 2017
NCT05430243		Empagliflozin as a Novel Therapy in Refractory Ascites	P2/P3	completed	42	Alexandria University	Apr 2022
NCT04917692		Empagliflozin in Adolescent Diabetes	P4	withdrawn	0	Ohio State University	Jul 2021
NCT05162014		To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin	—	completed	494,679	Boehringer Ingelheim	Dec 2021
NCT05200793		Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome	P4	unknown	75	Alexandria University	Dec 2021
NCT04520646		A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy	N/A	unknown	10	Huashan Hospital	Sep 2020
NCT04531462		A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years	P4	completed	129	Boehringer Ingelheim	Oct 2020
NCT05057819		Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass	P4	completed	22	Insel Gruppe AG, University Hospital Bern	Dec 2021
NCT05109949		Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes	P3	unknown	72	Centro Universitario de Ciencias de la Salud, Mexico	Mar 2020
NCT04461041	EMPA-HEART 2	Empagliflozin and Cardiac Remodelling in People Without Diabetes	P4	completed	169	Unity Health Toronto	Apr 2021
NCT02864914		Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors	—	completed	333,580	Boehringer Ingelheim	Mar 2016
NCT04702490		Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH	P2	unknown	120	Metacrine, Inc.	Dec 2020
NCT03748810		Head-to-head Comparison of Empagliflozin and Dapagliflozin	—	completed	600	Chungbuk National University Hospital	Jan 2016
NCT03646292		Antidiabetic Drugs for Steatotic Liver Disease	P4	completed	51	Yonsei University	Dec 2018
NCT03993132	GLP1-RA	A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes	—	completed	26,774	Boehringer Ingelheim	Oct 2018
NCT05102071	HCRU	Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas	—	withdrawn	0	Boehringer Ingelheim	Nov 2021
NCT04221152	EMPIRE-02	A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )	P3	unknown	8	Kobe University	Feb 2020
NCT05036421	UGT	Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin	P3	completed	18	Ain Shams University	Feb 2022
NCT03087773	EMMY	Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction	P3	completed	476	Medical University of Graz	May 2017
NCT04735042	UTI-flog	SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.	—	completed	60	University of Pisa	Oct 2020
NCT06632561	HFrEF	Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus	P4	completed	74	Ashraf Wasfy Beshay Aziz	Jul 2021
NCT04233801		A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin	P3	completed	219	Boehringer Ingelheim	Apr 2020
NCT04243850	REGROUP	REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations	P4	withdrawn	0	Amsterdam UMC, location VUmc	Jul 2020
NCT05359341		Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?	N/A	completed	175	Sadat City University	Sep 2020
NCT03753087		Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus	P4	completed	70	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation	Jan 2019
NCT04910178		Follow-up of NAFLD Patients With MRI-PDFF	P4	completed	80	Asmaa Abdelfattah Elsayed	Dec 2020
NCT03852901		Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production	P1	completed	21	National Institute on Aging (NIA)	Mar 2019
NCT05229796		Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions	N/A	completed	26	Mutah University	May 2021
NCT03817463		A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes	—	completed	327,624	Boehringer Ingelheim	Apr 2019
NCT03202667	SANDx	Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study	P2/P3	completed	17	University Hospital, Basel, Switzerland	Dec 2017
NCT04183868	FIORE	Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)	P4	completed	26	University of Catanzaro	Apr 2016
NCT04018365	EMPIRE-01	A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance	P3	unknown	8	Kobe University	Sep 2019
NCT04295005		A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists	—	completed	24,500	Boehringer Ingelheim	Nov 2020
NCT05283057		Empagliflozin in Patients With Glomerulonephritis	P3	completed	50	Kasr El Aini Hospital	Feb 2020
NCT04238702	RECOLAR	Renohemodynamic Effects of Combined empagliflOzin and LosARtan	P4	completed	24	Amsterdam UMC, location VUmc	Nov 2020
NCT05083949	InPedILD®	A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together	P1	completed	32	Boehringer Ingelheim	Jul 2021
NCT04201496	CiQ-SGLT2	SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus	P1	completed	34	Ananda Basu, MD	Feb 2020
NCT04143581	EMPATHY	SGLT2 Inhibitors in Glomerular Hyperfiltration	P2	withdrawn	0	Mario Negri Institute for Pharmacological Research	Sep 2021
NCT05210517	UREX	SGLT2 Inhibition: Uric Acid Excretion Study	P4	completed	10	Amsterdam UMC, location VUmc	Oct 2020
NCT03807440		DIA_CENTRAL:T2D Treatment Pattern in Central Europe	—	completed	4,083	Boehringer Ingelheim	Aug 2019
NCT03979352	CLASS17	Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting	P3	completed	28	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Aug 2019
NCT04961931		Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease	N/A	unknown	45	Medical University of Lodz	Jan 2019
NCT05359432		Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus	P4	completed	120	Getz Pharma	Jul 2020
NCT04061200	EmpaSema	Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria	P4	unknown	80	Steno Diabetes Center Copenhagen	Nov 2019
NCT04937816		This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations	—	completed	16,746	Boehringer Ingelheim	Jun 2021
NCT04049045	EMPAG-HF	Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure	P2	completed	60	Christian Schulze	Sep 2019
NCT04157751		A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure	P3	completed	530	Boehringer Ingelheim	May 2020
NCT05946148	NAMELS-18	Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)	—	completed	78	National and Kapodistrian University of Athens	Jun 2018
NCT03057951		EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)	P3	completed	5,988	Boehringer Ingelheim	Mar 2017
NCT04215536		Replication of the EMPAREG Diabetes Trial in Healthcare Claims	—	completed	103,752	Brigham and Women's Hospital	Jul 2019
NCT03560375		Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol	P4	completed	100	Tel-Aviv Sourasky Medical Center	May 2018
NCT04431141		Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin	P1	completed	32	Handok Inc.	Sep 2020
NCT03764631		Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration	—	completed	1,502	Boehringer Ingelheim	Sep 2018
NCT04195243		Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus	P3	unknown	24	Centro Universitario de Ciencias de la Salud, Mexico	Dec 2019
NCT04131582	4T	Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes	P3	unknown	34	Universidad de Guanajuato	Sep 2019
NCT03554200		EMPA Acute Heart Failure	P2	terminated	19	RWTH Aachen University	Jun 2018
NCT04665284	SAFE-PAK	Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus	P4	completed	244	Getz Pharma	Jun 2019
NCT04215445		Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD	P4	unknown	90	National University of Malaysia	Dec 2019
NCT02932436	EmDia	Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics	P4	completed	144	Johannes Gutenberg University Mainz	Oct 2016
NCT03933956	(MEDiaN)	Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)	P3	terminated	2	Singapore General Hospital	Jan 2020
NCT04014192		Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus	P4	unknown	40	Peking Union Medical College Hospital	Sep 2019
NCT04138251	GLYCO-1B	Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency	P2	unknown	5	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Jun 2019
NCT03271879	ERA-HF	Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients	P4	unknown	128	Rambam Health Care Campus	Feb 2018
NCT03332212		A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin	P3	completed	72	Boehringer Ingelheim	Mar 2018
NCT03057977		EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)	P3	completed	3,730	Boehringer Ingelheim	Mar 2017
NCT03151343	SIMPLE	SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk	P3	completed	92	Caroline M Kistorp	Mar 2017
NCT03128528	ELSI	Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure	P2	completed	84	University of Erlangen-Nürnberg Medical School	Jul 2017
NCT03254849		Empagliflozin and Sympathetic Nerve Traffic	P4	completed	75	Profil Institut für Stoffwechselforschung GmbH	Dec 2017
NCT03485092	SUGAR-DM-HF	Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects	P4	completed	105	NHS Greater Glasgow and Clyde	Mar 2018
NCT03790787		Drug Interaction Study Between Dorzagliatin and Empagliflozin	P1	completed	16	Hua Medicine Limited	Apr 2019
NCT03713190	ESRD	Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).	P2	completed	25	University of Pisa	Sep 2018
NCT03030222	EMBRACE-HF	Empagliflozin Impact on Hemodynamics in Patients With Heart Failure	P4	completed	65	Saint Luke's Health System	Jul 2017
NCT03173963		Empaglifozin in Early Diabetic Kidney Disease	P3	withdrawn	0	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	May 2017
NCT03485222	EMPA-TROPISM	Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).	P4	completed	84	Icahn School of Medicine at Mount Sinai	May 2018
NCT03118336	EMPACEF	Impact of Empaglifozine on Cardiac Ectopic Fat	P3	completed	56	Assistance Publique Hopitaux De Marseille	Jun 2017
NCT01001962	PREHYPD	Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics	P4	unknown	1,054	Aristotle University Of Thessaloniki	Jan 2016
NCT02890745	EMPOX	The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes	P2	completed	31	Henrik Enghusen Poulsen	Nov 2016
NCT03198585	Empire HF	Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction	P2	completed	190	Morten Schou	Jun 2017
NCT04098575	EDCOS	A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes	—	completed	9,571	Boehringer Ingelheim	Sep 2019
NCT04497792	SAFARY	Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions	P4	completed	40	Research Institute for Complex Problems of Cardiovascular Diseases, Russia	Nov 2016
NCT03510000	CLASS15	Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin	N/A	completed	30	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	May 2018
NCT03227484		Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes	P2	completed	42	University Hospital Tuebingen	Jun 2017
NCT03448406		This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.	P3	completed	315	Boehringer Ingelheim	Mar 2018
NCT03448419		This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms	P3	completed	312	Boehringer Ingelheim	Mar 2018
NCT03200860	EMPA-RESPONSE	Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure	P2	completed	80	University Medical Center Groningen	Dec 2017
NCT03591991		Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI	N/A	unknown	128	Chinese PLA General Hospital	Oct 2018
NCT04061473	Px-Meal	Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion	N/A	completed	20	University Hospital, Gentofte, Copenhagen	Apr 2019
NCT03078101	EMPRA	EMPRA (EMPagliflozin and RAs in Kidney Disease)	P2	completed	51	Medical University of Vienna	Apr 2017
NCT03208465	ELITE	Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease	P4	completed	100	CHEOL WHAN LEE, M.D., Ph.D	Aug 2017
NCT02798744	SEESAW	SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.	P4	completed	68	University of Leicester	Dec 2016
NCT02632747		Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study	P2	completed	31	Boehringer Ingelheim	May 2016
NCT03504566	ROTATE-2	Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)	P4	withdrawn	0	Steno Diabetes Center Copenhagen	Nov 2017
NCT03027960	EMPA	Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects	P1	completed	21	Yale University	Jun 2017
NCT02752113	ELMI	Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes	P3	completed	101	Institut für Pharmakologie und Präventive Medizin	Apr 2016
NCT04143321		Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina	P4	completed	75	Isfahan University of Medical Sciences	Sep 2018
NCT03351478	SOTA-EMPA	Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin	P3	completed	770	Lexicon Pharmaceuticals	Nov 2017
NCT05132023		Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)	P1	completed	26	Genuine Research Center, Egypt	Mar 2019
NCT03462069		Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension	P2	completed	41	Sanofi	Mar 2018
NCT03642184		Efficacy and Safety of Empagliflozin in NODAT	P4	terminated	6	RenJi Hospital	Jul 2018
NCT03639545		The Effects of Empagliflozin on Arterial Wall Characteristics	P4	unknown	120	University Medical Centre Ljubljana	Mar 2018
NCT03132181	EMPA	Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes	P2	completed	40	RWTH Aachen University	Apr 2017
NCT03766724		Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults	P1	completed	42	Dong-A ST Co., Ltd.	Nov 2018
NCT02874807	SAND	Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study	P2/P3	completed	88	University Hospital, Basel, Switzerland	Sep 2016
NCT03226457	RECEDE-CHF	SGLT2 Inhibition in Combination With Diuretics in Heart Failure	P4	completed	23	University of Dundee	Dec 2017
NCT02768220		The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products	P4	withdrawn	0	Northwell Health	Dec 2017
NCT02918591	EMP	Cardiovascular Effects of Empagliflozine	N/A	unknown	10	Tel Aviv University	Nov 2017
NCT03093103	EMPA-REIN	Empagliflozin and Renal Oxygenation in Healthy Volunteers	P2	completed	45	Centre Hospitalier Universitaire Vaudois	Mar 2017
NCT03565458		Gemigliptin, Dapagliflozin, Empagliflozin DDI Study	P1	unknown	48	LG Chem	Apr 2018
NCT02964715		The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes	P4	unknown	25	University of Malaya	Nov 2016
NCT02833415		Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging	P4	completed	40	University of Texas Southwestern Medical Center	Mar 2016
NCT03458715		The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin	P4	unknown	120	Mackay Memorial Hospital	Sep 2017
NCT04927858		A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017	—	completed	460,558	Boehringer Ingelheim	Apr 2018
NCT03629054		This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills	P1	completed	30	Boehringer Ingelheim	Aug 2018
NCT03895229		The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin	P1	completed	16	Ain Shams University	Oct 2018
NCT02998970	EMPA-HEART	Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes	P4	unknown	97	Unity Health Toronto	Jan 2017
NCT03200782	Hypo-BEAR	Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study	N/A	completed	12	University Hospital, Basel, Switzerland	May 2017
NCT02637973	EmLiFa	Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes	P4	completed	84	The Deutsche Diabetes Forschungsgesellschaft e.V.	Dec 2015
NCT02985242		Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema	P4	terminated	6	Hannover Medical School	Jun 2017
NCT02792400		The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors	N/A	completed	24	University Hospital, Gentofte, Copenhagen	May 2016
NCT03157414	EMPA-RenalTx	Empagliflozin in Renal Transplant Recipients	P4	completed	49	Oslo University Hospital	Nov 2016
NCT03492580		A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease	—	completed	714,582	Janssen Research & Development, LLC	Feb 2018
NCT03152552		A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure	P2	terminated	125	Novartis Pharmaceuticals	Jul 2017
NCT03113110	EMPTRA-DM	Empagliflozin in Post-Transplantation Diabetes Mellitus	P2	completed	16	Medical University of Vienna	Jan 2017
NCT03771781		Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.	N/A	completed	48	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Apr 2018
NCT03008551		Empagliflozin vs Metformin in PCOS	P2/P3	completed	40	Hull University Teaching Hospitals NHS Trust	Aug 2017
NCT03050229		SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)	P4	completed	174	Jichi Medical University	Jan 2017
NCT02863328	PIONEER 2	Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus	P3	completed	822	Novo Nordisk A/S	Aug 2016
NCT03060980		Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin	P3	terminated	245	Intarcia Therapeutics	Mar 2017
NCT02589639		Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus	P4	completed	269	Boehringer Ingelheim	Oct 2015
NCT02686476	E-LIFT	Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes	N/A	completed	100	Medanta, The Medicity, India	Mar 2016
NCT03259490		This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood	P1	completed	30	Boehringer Ingelheim	Aug 2017
NCT03249506	T2DM	Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)	—	completed	25,358	Janssen Research & Development, LLC	May 2016
NCT02414958	EASE-2	Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)	P3	completed	730	Boehringer Ingelheim	Jun 2015
NCT04203914	EMPHYT	Short Term Effect of Empagliflozin in Hypertension	P4	completed	15	Yaounde Central Hospital	Jan 2017
NCT02728453	EMPATROPHY	SGLT2 Inhibition and Left Ventricular Mass	P4	terminated	7	Hannover Medical School	Apr 2016
NCT02580591	EASE-3	Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)	P3	completed	977	Boehringer Ingelheim	Dec 2015
NCT02964572		Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes	N/A	completed	61	Yonsei University	Nov 2016
NCT02489968		Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus	P3	completed	880	Boehringer Ingelheim	May 2015
NCT02589626		Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA	P4	completed	65	Boehringer Ingelheim	Oct 2015
NCT02182830	BI 10773	24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension	P3	completed	166	Boehringer Ingelheim	Jul 2014
NCT02453555		Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus	P3	completed	275	Boehringer Ingelheim	May 2015
NCT01984606		Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes	P3	withdrawn	0	Boehringer Ingelheim	Jan 2015
NCT03059056		Pharmacokinetic Evaluation of Empagliflozin	P1	completed	6	British University In Egypt	Feb 2017
NCT02821910		Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets	P1	completed	50	Boehringer Ingelheim	Jul 2016
NCT03050619		Characteristics of Empagliflozin Initiators	—	completed	31,908	Boehringer Ingelheim	Sep 2016
NCT02815644		Empa/Lina FDC Food Effect Study (Japan)	P1	completed	22	Boehringer Ingelheim	Jul 2016
NCT02702011		Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus	P2	completed	48	Boehringer Ingelheim	Mar 2016
NCT02854748		Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin	P1	unknown	30	Chong Kun Dang Pharmaceutical	Aug 2016
NCT02729766	DIVE	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study	P2/P3	completed	15	University Hospital, Basel, Switzerland	Mar 2016
NCT02758171		Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects	P1	completed	56	Boehringer Ingelheim	May 2016
NCT02471963		Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function	P3	completed	74	University of Erlangen-Nürnberg Medical School	Dec 2014
NCT02121483		Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus	P1	completed	27	Boehringer Ingelheim	Jun 2014
NCT02401880		Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology	P4	completed	89	Profil Institut für Stoffwechselforschung GmbH	May 2015
NCT02577315		Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions	P1	completed	25	Boehringer Ingelheim	Sep 2015
NCT01867307		Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls	P2	completed	39	Boehringer Ingelheim	Jun 2013
NCT01734785		Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes	P3	completed	607	Boehringer Ingelheim	Feb 2013
NCT02266472		Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female	P1	completed	30	Boehringer Ingelheim	Nov 2014
NCT01719003		Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes	P3	completed	1,413	Boehringer Ingelheim	Oct 2012
NCT02230995		Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects	P1	completed	30	Boehringer Ingelheim	Sep 2014
NCT02102932		Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers	P1	completed	96	Boehringer Ingelheim	May 2014
NCT02106923	XR	Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets	P1	completed	72	Boehringer Ingelheim	Apr 2014
NCT01969747		Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days	P2	completed	75	Boehringer Ingelheim	Nov 2013
NCT02028767		Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets	P1	completed	32	Boehringer Ingelheim	Jan 2014
NCT01975220		Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets	P1	completed	72	Boehringer Ingelheim	Oct 2013
NCT01947855	PPG	Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus	P3	completed	60	Boehringer Ingelheim	Sep 2013
NCT01649297	BI 10773	A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy	P2	completed	983	Boehringer Ingelheim	Oct 2012
NCT01844531		Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets	P1	completed	24	Boehringer Ingelheim	Apr 2013
NCT01811953		Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together	P1	completed	48	Boehringer Ingelheim	Mar 2013
NCT01672788		Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets	P1	completed	36	Boehringer Ingelheim	Aug 2012
NCT01634100	BI 10773	Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid	P1	completed	18	Boehringer Ingelheim	Jun 2012
NCT01451775		Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.	P1	completed	18	Boehringer Ingelheim	Oct 2011
NCT02782624		Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers	P1	completed	16	Boehringer Ingelheim	Sep 2009

Empagliflozin clinical trials: frequently asked questions

How many Empagliflozin clinical trials are there?: 428 Empagliflozin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 84 are actively recruiting participants. 215 are marked completed.
Are Empagliflozin clinical trials recruiting in 2026?: Yes — 84 Empagliflozin trials are actively recruiting in 2026, with 412 U.S. sites across 44 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Empagliflozin being studied for?: Empagliflozin is being studied for Diabetes Mellitus, Type 2, Heart Failure, Type 2 Diabetes, Healthy, Type 2 Diabetes Mellitus and 319 more. The trials are grouped by indication on this page.
What phase is Empagliflozin in?: Empagliflozin clinical trials span 116 Phase 4, 78 Phase 3, 68 Phase 2, 64 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Empagliflozin clinical trials?: The lead sponsor across the most Empagliflozin trials is Boehringer Ingelheim, with 223 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Empagliflozinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 26, 2026.

Related pages on Hipa.ai:

Empagliflozin overview Empagliflozin evidence & publications